



(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 14/31 (2006.01)
A61K 39/285 (2006.01) C12N 5/00 (2006.01)

(21) International Application Number:

PCT/EP2017/054043

(22) International Filing Date:

22 February 2017 (22.02.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

16156786.2 22 February 2016 (22.02.2016) EP

(71) Applicant: EVAXION BIOTECH APS [DK/DK]; Ole Maaløes Vej 3, 2200 Copenhagen N (DK).

(72) Inventors: IVERSEN MØLLER, Niels; Fagerlund 13A, 2950 Vedbæk (DK). HOLM MATTSSON, Andreas; Norasvej 15, 1.floor, 2920 Charlottenlund (DK).

(74) Agent: INSPICOS P/S; Kogle Allé 2, 2970 Hørsholm (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: PROTEINS AND NUCLEIC ACIDS USEFUL IN VACCINES TARGETING STAPHYLOCOCCUS AUREUS




Fig. 3

(57) Abstract: The present invention relates to proteins and nucleic acids derived from Staphylococcus aureus as well as therapeutic and diagnostic uses of the proteins and nucleic acids.

PROTEINS AND NUCLEIC ACIDS USEFUL IN VACCINES TARGETING STAPHYLOCOCCUS AUREUS

FIELD OF THE INVENTION

The present invention relates to the field of antimicrobial prophylaxis and therapy. In particular the present invention relates to novel proteins and polynucleotides derived from *Staphylococcus aureus*. The invention further relates to vectors comprising the polynucleotides, transformed host organisms expressing the polynucleotides, antibodies (mono- or polyclonal) specific for the polypeptides as well as diagnostic, prophylactic and therapeutic uses and methods. Finally, also methods of preparation are part of the invention.

10 BACKGROUND OF THE INVENTION

Bacterial infections are in most instances successfully treated by administration of antibiotics to patients in need thereof. However, due to careless or thoughtless use of powerful antibiotics, many pathological germs become resistant against antibiotics over time. One threatening example is *Staphylococcus aureus*. In particular in hospitals this bacterium is of relevance. So-called Methicillin Resistant S. Aureus (MRSA) strains jeopardize patient's survival in hospitals, in particular after surgery.

Vaccination is considered to be a very effective method of preventing infectious diseases in human and veterinary health care. Vaccination is the administration of immunogenically effective amounts of antigenic material (the vaccine) to produce immunity to a disease/disease-causing pathogenic agent. Vaccines have contributed to the eradication of smallpox, the near eradication of polio, and the control of a variety of diseases, including rubella, measles, mumps, chickenpox, typhoid fever.

Before "the genomic era", vaccines were based on killed or live attenuated, microorganisms, or parts purified from them. Subunit vaccines are considered as a modern upgrade of these types of vaccine, as the subunit vaccines contain one or more protective antigens, which are more or less the weak spot of the pathogen. Hence, in order to develop subunit vaccines, it is critical to identify the proteins, which are important for inducing protection and to eliminate others.

An antigen is said to be protective if it is able to induce protection from subsequent challenge by a disease-causing infectious agent in an appropriate animal model following immunization.

The empirical approach to subunit vaccine development, which includes several steps, begins with pathogen cultivation, followed by purification into components, and then testing of antigens for protection. Apart from being time and labour consuming, this approach has several limitations that can lead to failure. It is not possible to develop vaccines using this approach for microorganisms, which cannot easily be cultured and only allows for the identification of the antigens, which can be obtained in sufficient quantities. The empirical approach has a tendency to focus on the most abundant proteins, which in some cases are not immuno-protective. In other cases, the antigen expressed during *in vivo* infection is not expressed during *in vitro* cultivation. Furthermore, antigen discovery by use of the empirical approach demands an extreme amount of proteins in order to discover the protective antigens, which are like finding needles in the haystack. This renders it a very expensive approach, and it limits the vaccine development around diseases, which is caused by pathogens with a large genome or disease areas, which perform badly in a cost-effective perspective.

OBJECT OF THE INVENTION

It is an object of embodiments of the invention to provide *S. aureus* derived antigenic polypeptides that may serve as constituents in vaccines against *S. aureus* infections and in diagnosis of *S. aureus* infections. It is also an object to provide nucleic acids, vectors, transformed cells, vaccine compositions, and other useful means for molecular cloning as well as for therapy and diagnosis with relevance for *S. aureus*.

SUMMARY OF THE INVENTION

It has been found by the present inventor(s) that *S. aureus*, in particular drug resistant *S. aureus*, expresses a number of hitherto unknown putatively surface exposed proteins which are candidates as vaccine targets as well as candidates as immunizing agents for preparation of antibodies that target *S. aureus*.

The present assignee has previously filed patent applications relating to a number of immunogenic peptides from *S. aureus*. The polypeptides of the present invention are useful as (vaccine) immunogens per se but also in combination with any one of the immunogens disclosed in WO 2012/136653 and/or WO 2015/053899.

So, in a first aspect the present invention relates to a polypeptide comprising
a) an amino acid sequence selected from the group consisting of any one of SEQ ID NO: 1 and SEQ ID NO: 2, or

b) an amino acid sequence consisting of at least or exactly or at most 5 contiguous amino acid residues from SEQ ID NO: 1 or 2, or

c) an amino acid sequence having a sequence identity of at least 60% with the amino acid sequence of a),

5 d) an amino acid sequence having a sequence identity of at least 60% with the amino acid sequence of b), or

e) an assembly of amino acids derived from any one of SEQ ID NOs: 1-2, which has essentially the same 3D conformation as in the protein from which said assembly is derived so as to constitute a B-cell epitope, said polypeptide being antigenic in a mammal.

10 In another aspect, the invention relates to an isolated nucleic acid fragment, which comprises

i) a nucleotide sequence encoding a polypeptide of the invention, or

ii) a nucleotide sequence consisting of any one of SEQ ID NOs: 3-6.

iii) a nucleotide sequence consisting of at least or exactly or at most 10 consecutive nucleotides in any one of SEQ ID NOs: 3-6,

15 iv) a nucleotide sequence having a sequence identity of at least 60% with the nucleotide sequence in i) or ii),

v) a nucleotide sequence having a sequence identity of at least 60% with the nucleotide sequence in iii),

vi) a nucleotide sequence complementary to the nucleotide sequence in i)-v), or

20 vii) a nucleotide sequence which hybridizes under stringent conditions with the nucleotide sequence in i)-vi).

In a third aspect, the invention relates to a vector comprising the nucleic acid of the invention, such as a cloning vector or an expression vector.

25 In fourth aspect, the invention relates to a cell which is transformed so as to carry the vector of the invention.

In a fifth aspect, the invention relates to a pharmaceutical composition comprising a polypeptide of the invention, a nucleic acid fragment of the invention, a vector of the invention, or a transformed cell of the invention, and a pharmaceutically acceptable carrier, vehicle or diluent.

30 In a sixth aspect, the invention relates to a method for inducing immunity in an animal by administering at least once an immunogenically effective amount of a polypeptide of the invention, a nucleic acid fragment of the invention, a vector of the invention, a transformed cell of the invention, or a pharmaceutical composition of the fifth aspect of the invention so as to induce adaptive immunity against *S. aureus* in the animal.

In a seventh and eighth aspect, the invention relates to 1) a polyclonal antibody in which the antibodies specifically bind to at least one polypeptide of the invention, and which is essentially free from antibodies binding specifically to other *S. aureus* polypeptides, and to 2) an isolated monoclonal antibody or antibody analogue which binds specifically to a polypeptide of the invention. In a related ninth aspect, the invention relates to a pharmaceutical composition comprising such a polyclonal or monoclonal antibody and a pharmaceutically acceptable carrier, vehicle or diluent.

In a 10th aspect, the invention relates to a method for prophylaxis, treatment or amelioration of infection with *S. aureus*, comprising administering a therapeutically effective amount of an antibody of the 7th or 8th aspect of the invention or a pharmaceutical composition of the eighth aspect to an individual in need thereof.

In an 11th aspect, the invention relates to a method for determining, quantitatively or qualitatively, the presence of *S. aureus*, in particular the presence of multi-resistant *S. aureus*, in a sample, the method comprising contacting the sample with an antibody of aspects 8 or 9 of the invention and detecting the presence of antibody bound to material in the sample.

In an 12th aspect of the invention is provided a method for determining, quantitatively or qualitatively, the presence of antibodies specific for *S. aureus*, in particular the presence of antibodies specific for multi-resistant *S. aureus*, in a sample, the method comprising contacting the sample with a polypeptide of the invention and detecting the presence of antibody that specifically bind said polypeptide.

In a 13th aspect, the invention relates to a method for determining, quantitatively or qualitatively, the presence of a nucleic acid characteristic of *S. aureus*, in particular the presence of a nucleic acid characteristic of multi-resistant *S. aureus*, in a sample, the method comprising contacting the sample with a nucleic acid fragment of the invention and detecting the presence of nucleic acid in the sample that hybridizes to said nucleic acid fragment.

In a 14th aspect, the invention relates to a method for the preparation of the polypeptide of the invention, comprising

- culturing a transformed cell of the present invention, which is capable of expressing the nucleic acid of the invention, under conditions that facilitate that the transformed cell expresses the nucleic acid fragment of the invention, which encodes a polypeptide of the invention, and subsequently recovering said polypeptide, or
- preparing said polypeptide by means of solid or liquid phase peptide synthesis.

In a 15th aspect, the invention relates to a method for determining whether a substance, such as an antibody, is potentially useful for treating infection with *S. aureus*, the method comprising contacting the polypeptide of the invention with the substance and subsequently establishing whether the substance has at least one of the following characteristics:

- 5 1) the ability to bind specifically to said polypeptide,
- 2) the ability to compete with said polypeptide for specific binding to a ligand/receptor, and
- 3) the ability to specifically inactivate said polypeptide.

Finally, in a 16th aspect, the invention relates to a method for determining whether a substance, such as a nucleic acid, is potentially useful for treating infection with *S. aureus*,
10 the method comprising contacting the substance with the nucleic acid fragment of claim of the invention and subsequently establishing whether the substance has either the ability to

- 1) bind specifically to the nucleic acid fragment, or
- 2) bind specifically to a nucleic acid that hybridizes specifically with the nucleic acid fragment.

15 LEGENDS TO THE FIGURES

Fig. 1: Survival of mice immunized with SAR1262-25-519.

The survival of mice immunized with SAR1262-25-519 was significantly different from that of mice in the control group. 86% of the SAR1262-25-519 immunized mice survived the lethal *S. aureus* challenge, which was significantly different from the 17% survival of the control
20 group. The data were analysed using log-rank (Mantel-Cox) test, P = 0.0322.

Fig. 2: Antibody production against SAR1262-25-519 in 8 immunized mice.

The antibody titre was measured in plasma from the 8 mice immunized with SAR1262-25-519. Each curve represents the antibody titre of one mouse, see # ID number in the figure. The Y-axis represents the absorbance measured at 490 nm – 650 nm (reference), and the X-
25 axis shows the plasma dilution. There was some variation in the antibody responses to SAR1262-25-519. Mouse #16 had to be euthanized prior to challenge.

Fig. 3: Survival of mice immunized with SAR2635-1-199.

The survival of mice immunized with SAR2635-1-199 was significantly higher than that of mice in the control group. 63% of the SAR2635-1-199 immunized mice survived the lethal *S. aureus* challenge compared to 13% survival of the control group. The data were analysed
30 using log-rank (Mantel-Cox) test, P = 0.0067.

Fig. 4: Survival of mice immunized with SAR2635-1-199.

The survival of mice immunized with SAR2635-1-199 was significantly higher than that of mice in the control group. 95 % of the SAR2635-1-199 immunized mice survived the lethal *S. aureus* challenge, compared to 55 % survival of the control group. The data were analysed using log-rank (Mantel-Cox) test, $P = 0.0046$.

Fig. 5: Survival of mice immunized with SAR1262-25-519.

The survival of mice immunized with SAR1262-25-519 was significantly higher than that of mice in the control group. 85% of the SAR1262-25-519 immunized mice survived the lethal *S. aureus* challenge, compared to 55% survival of the control group. The data were analysed using log-rank (Mantel-Cox) test, $P = 0.0478$.

DETAILED DISCLOSURE OF THE INVENTION

Definitions

The term "polypeptide" is in the present context intended to mean both short peptides of from 2 to 10 amino acid residues, oligopeptides of from 11 to 100 amino acid residues, and polypeptides of more than 100 amino acid residues. Further-more, the term is also intended to include proteins, i.e. functional biomolecules comprising at least one polypeptide; when comprising at least two polypeptides, these may form complexes, be covalently linked, or may be non-covalently linked. The polypeptide (s) in a protein can be glycosylated and/or lipidated and/or comprise prosthetic groups.

The term "subsequence" means any consecutive stretch of at least 3 amino acids or, when relevant, of at least 3 nucleotides, derived directly from a naturally occurring amino acid sequence or nucleic acid sequence, respectively

The term "amino acid sequence" designates the order in which amino acid residues, connected by peptide bonds, lie in the chain in peptides and proteins.

The term "adjuvant" has its usual meaning in the art of vaccine technology, i.e. a substance or a composition of matter which is 1) not in itself capable of mounting a specific immune response against the immunogen of the vaccine, but which is 2) nevertheless capable of enhancing the immune response against the immunogen. Or, in other words, vaccination with the adjuvant alone does not provide an immune response against the immunogen, vaccination with the immunogen may or may not give rise to an immune response against the immunogen, but the combined vaccination with immunogen and adjuvant induces an

immune response against the immunogen which is stronger than that induced by the immunogen alone.

"Sequence identity" is in the context of the present invention determined by comparing 2 optimally aligned sequences of equal length (e.g. DNA, RNA or amino acid) according to the following formula: $(N_{\text{ref}} - N_{\text{dif}}) \cdot 100 / N_{\text{ref}}$, wherein N_{ref} is the number of residues in one of the 2 sequences and N_{dif} is the number of residues which are non-identical in the two sequences when they are aligned over their entire lengths and in the same direction. So, two sequences 5'-ATTCGGAACC-3' and 5'- ATACGGGACC-3' will provide the sequence identity 80% ($N_{\text{ref}}=10$ and $N_{\text{dif}}=2$).

10 An "assembly of amino acids" means two or more amino acids bound together by physical or chemical means.

The "3D conformation" is the 3 dimensional structure of a biomolecule such as a protein. In monomeric polypeptides/proteins, the 3D conformation is also termed "the tertiary structure" and denotes the relative locations in 3 dimensional space of the amino acid residues forming the polypeptide.

"An immunogenic carrier" is a molecule or moiety to which an immunogen or a hapten can be coupled in order to enhance or enable the elicitation of an immune response against the immunogen/hapten. Immunogenic carriers are in classical cases relatively large molecules (such as tetanus toxoid, KLH, diphtheria toxoid etc.) which can be fused or conjugated to an immunogen/hapten, which is not sufficiently immunogenic in its own right – typically, the immunogenic carrier is capable of eliciting a strong T-helper lymphocyte response against the combined substance constituted by the immunogen and the immunogenic carrier, and this in turn provides for improved responses against the immunogen by B-lymphocytes and cytotoxic lymphocytes. More recently, the large carrier molecules have to a certain extent been substituted by so-called promiscuous T-helper epitopes, *i.e.* shorter peptides that are recognized by a large fraction of HLA haplotypes in a population, and which elicit T-helper lymphocyte responses.

A "T-helper lymphocyte response" is an immune response elicited on the basis of a peptide, which is able to bind to an MHC class II molecule (e.g. an HLA class II molecule) in an antigen-presenting cell and which stimulates T-helper lymphocytes in an animal species as a consequence of T-cell receptor recognition of the complex between the peptide and the MHC Class II molecule presenting the peptide.

An "immunogen" is a substance of matter which is capable of inducing an adaptive immune response in a host, whose immune system is confronted with the immunogen. As such, immunogens are a subset of the larger genus "antigens", which are substances that can be recognized specifically by the immune system (e.g. when bound by antibodies or,

5 alternatively, when fragments of the are antigens bound to MHC molecules are being recognized by T-cell receptors) but which are not necessarily capable of inducing immunity - an antigen is, however, always capable of *eliciting* immunity, meaning that a host that has an established memory immunity against the antigen will mount a specific immune response against the antigen.

10 A "hapten" is a small molecule, which can neither induce nor elicit an immune response, but if conjugated to an immunogenic carrier, antibodies or TCRs that recognize the hapten can be induced upon confrontation of the immune system with the hapten carrier conjugate.

An "adaptive immune response" is an immune response in response to confrontation with an antigen or immunogen, where the immune response is specific for antigenic determinants of
15 the antigen/immunogen - examples of adaptive immune responses are induction of antigen specific antibody production or antigen specific induction/activation of T helper lymphocytes or cytotoxic lymphocytes.

A "protective, adaptive immune response" is an antigen-specific immune response induced in a subject as a reaction to immunization (artificial or natural) with an antigen, where the
20 immune response is capable of protecting the subject against subsequent challenges with the antigen or a pathology-related agent that includes the antigen. Typically, prophylactic vaccination aims at establishing a protective adaptive immune response against one or several pathogens.

"Stimulation of the immune system" means that a substance or composition of matter
25 exhibits a general, non-specific immunostimulatory effect. A number of adjuvants and putative adjuvants (such as certain cytokines) share the ability to stimulate the immune system. The result of using an immunostimulating agent is an increased "alertness" of the immune system meaning that simultaneous or subsequent immunization with an immunogen induces a significantly more effective immune response compared to isolated use of the
30 immunogen.

Hybridization under "stringent conditions" is herein defined as hybridization performed under conditions by which a probe will hybridize to its target sequence, to a detectably greater degree than to other sequences. Stringent conditions are target-sequence-dependent and will differ depending on the structure of the polynucleotide. By controlling the stringency of the

hybridization and/or washing conditions, target sequences can be identified which are 100% complementary to a probe (homologous probing). Alternatively, stringency conditions can be adjusted to allow some mismatching in sequences so that lower degrees of similarity are detected (heterologous probing). Specificity is typically the function of post-hybridization washes, the critical factors being the ionic strength and temperature of the final wash solution. Generally, stringent wash temperature conditions are selected to be about 5°C to about 2°C lower than the melting point (T_m) for the specific sequence at a defined ionic strength and pH. The melting point, or denaturation, of DNA occurs over a narrow temperature range and represents the disruption of the double helix into its complementary single strands. The process is described by the temperature of the midpoint of transition, T_m , which is also called the melting temperature. Formulas are available in the art for the determination of melting temperatures.

The term "animal" is in the present context in general intended to denote an animal species (preferably mammalian), such as *Homo sapiens*, *Canis domesticus*, etc. and not just one single animal. However, the term also denotes a population of such an animal species, since it is important that the individuals immunized according to the method of the invention substantially all will mount an immune response against the immunogen of the present invention.

As used herein, the term "antibody" refers to a polypeptide or group of polypeptides composed of at least one antibody combining site. An "antibody combining site" is the three-dimensional binding space with an internal surface shape and charge distribution complementary to the features of an epitope of an antigen, which allows a binding of the antibody with the antigen. "Antibody" includes, for example, vertebrate antibodies, hybrid antibodies, chimeric antibodies, humanised antibodies, altered antibodies, univalent antibodies, Fab proteins, and single domain antibodies.

"Specific binding" denotes binding between two substances which goes beyond binding of either substance to randomly chosen substances and also goes beyond simple association between substances that tend to aggregate because they share the same overall hydrophobicity or hydrophilicity. As such, specific binding usually involves a combination of electrostatic and other interactions between two conformationally complementary areas on the two substances, meaning that the substances can "recognize" each other in a complex mixture.

The term "vector" is used to refer to a carrier nucleic acid molecule into which a heterologous nucleic acid sequence can be inserted for introduction into a cell where it can be replicated and expressed. The term further denotes certain biological vehicles useful for the same

purpose, e.g. viral vectors and phage – both these infectious agents are capable of introducing a heterologous nucleic acid sequence

The term "expression vector" refers to a vector containing a nucleic acid sequence coding for at least part of a gene product capable of being transcribed. In some cases, when the transcription product is an RNA molecule such as an mRNA molecule, this is in turn translated into a protein, polypeptide, or peptide.

Specific embodiments of the invention

The polypeptides of the invention

In some embodiments the at least or exactly 5 contiguous amino acids referred to in option b) in the definition of the first aspect of the invention constitute at least or exactly or at most 6 contiguous amino acid residues, such as at least or exactly or at most 7, at least or exactly or at most 8, at least or exactly or at most 9, at least or exactly or at most 10, at least or exactly or at most 11, at least or exactly or at most 12, at least or exactly or at most 13, at least or exactly or at most 14, at least or exactly or at most 15, at least or exactly or at most 16, at least or exactly or at most 17, at least or exactly or at most 18, at least or exactly or at most 19, at least or exactly or at most 20, at least or exactly or at most 21, at least or exactly or at most 22, at least or exactly or at most 23, at least or exactly or at most 24, at least or exactly or at most 25, at least or exactly or at most 26, at least or exactly or at most 27 at least or exactly or at most 28, at least or exactly or at most 29, at least or exactly or at most 30, at least or exactly or at most 31, at least or exactly or at most 32, at least or exactly or at most 33, at least or exactly or at most 34, at least or exactly or at most 35, at least or exactly or at most 36, at least or exactly or at most 37, at least or exactly or at most 38, at least or exactly or at most 39, at least or exactly or at most 40, at least or exactly or at most 41, at least or exactly or at most 42, at least or exactly or at most 43, at least or exactly or at most 44, at least or exactly or at most 45, at least or exactly or at most 46, at least or exactly or at most 47, at least or exactly or at most 48, at least or exactly or at most 49, at least or exactly or at most 50, at least or exactly or at most 51, at least or exactly or at most 52, at least or exactly or at most 53, at least or exactly or at most 54, at least or exactly or at most 55, at least or exactly or at most 56, at least or exactly or at most 57, at least or exactly or at most 58, at least or exactly or at most 59, at least or exactly or at most 60, at least or exactly or at most 61, at least or exactly or at most 62, at least or exactly or at most 63, at least or exactly or at most 64, at least or exactly or at most 65, at least or exactly or at most 66, at least or exactly or at most 67, at least or exactly or at most 68, at least or exactly or at most 69, at least or exactly or at most 70, at least or exactly or at most 71, at least or exactly or at most 72, at least or exactly or at most 73, at least or exactly or

[illegible]

exactly or at most 179, at least or exactly or at most 180, at least or exactly or at most 181, at least or exactly or at most 182, at least or exactly or at most 183, at least or exactly or at most 184, at least or exactly or at most 185, at least or exactly or at most 186, at least or exactly or at most 187, at least or exactly or at most 188, at least or exactly or at most 189, at least or exactly or at most 190, at least or exactly or at most 191, at least or exactly or at most 192, at least or exactly or at most 193, at least or exactly or at most 194, at least or exactly or at most 195, at least or exactly or at most 196, at least or exactly or at most 197, or at least or exactly or at most 198 contiguous amino acid residues of SEQ ID NO: 1.

In some embodiments the at least or exactly 5 contiguous amino acids referred to in option

b) in the definition of the first aspect of the invention constitute at least or exactly or at most 6 contiguous amino acid residues, such as at least or exactly or at most 7, at least or exactly or at most 8, at least or exactly or at most 9, at least or exactly or at most 10, at least or exactly or at most 11, at least or exactly or at most 12, at least or exactly or at most 13, at least or exactly or at most 14, at least or exactly or at most 15, at least or exactly or at most 16, at least or exactly or at most 17, at least or exactly or at most 18, at least or exactly or at most 19, at least or exactly or at most 20, at least or exactly or at most 21, at least or exactly or at most 22, at least or exactly or at most 23, at least or exactly or at most 24, at least or exactly or at most 25, at least or exactly or at most 26, at least or exactly or at most 27 at least or exactly or at most 28, at least or exactly or at most 29, at least or exactly or at most 30, at least or exactly or at most 31, at least or exactly or at most 32, at least or exactly or at most 33, at least or exactly or at most 34, at least or exactly or at most 35, at least or exactly or at most 36, at least or exactly or at most 37, at least or exactly or at most 38, at least or exactly or at most 39, at least or exactly or at most 40, at least or exactly or at most 41, at least or exactly or at most 42, at least or exactly or at most 43, at least or exactly or at most 44, at least or exactly or at most 45, at least or exactly or at most 46, at least or exactly or at most 47, at least or exactly or at most 48, at least or exactly or at most 49, at least or exactly or at most 50, at least or exactly or at most 51, at least or exactly or at most 52, at least or exactly or at most 53, at least or exactly or at most 54, at least or exactly or at most 55, at least or exactly or at most 56, at least or exactly or at most 57, at least or exactly or at most 58, at least or exactly or at most 59, at least or exactly or at most 60, at least or exactly or at most 61, at least or exactly or at most 62, at least or exactly or at most 63, at least or exactly or at most 64, at least or exactly or at most 65, at least or exactly or at most 66, at least or exactly or at most 67, at least or exactly or at most 68, at least or exactly or at most 69, at least or exactly or at most 70, at least or exactly or at most 71, at least or exactly or at most 72, at least or exactly or at most 73, at least or exactly or at most 74, at least or exactly or at most 75, at least or exactly or at most 76, at least or exactly or at most 77, at least or exactly or at most 78, at least or exactly or at most 79, at least or exactly or at most 80, at least or exactly or at most 81, at least or exactly or at most

[illegible]

[illegible]

[illegible]

[illegible]

exactly or at most 499, at least or exactly or at most 500, at least or exactly or at most 501, at least or exactly or at most 502, at least or exactly or at most 503, at least or exactly or at most 504, at least or exactly or at most 505, at least or exactly or at most 506, at least or exactly or at most 507, at least or exactly or at most 508, at least or exactly or at most 509, at least or exactly or at most 510, at least or exactly or at most 511, at least or exactly or at most 512, at least or exactly or at most 513, at least or exactly or at most 514, at least or exactly or at most 515, at least or exactly or at most 516, at least or exactly or at most 517, or at least or exactly or at most 518 contiguous amino acid residues of SEQ ID NO: 2.

Another way to phrase this is that for each of SEQ ID NOs: 1 and 2 the number of the contiguous amino acid residues is at least or exactly or at most N-n, where N is the length of the sequence ID in question and n is any integer between N-5 and 0; that is, the at least 5 contiguous amino acids can be at least any number between 5 and the length of the reference sequence minus one, in increments of one.

In some embodiments, the polypeptide of the invention also has a sequence identity with the amino acid sequence of a) defined above of at least 61%, such as at least 63%, at least 63% at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%. Similarly, the polypeptide of the invention in some embodiments also has a sequence identity with the amino acid sequence of b) defined above of at least 61%, such as at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.

In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98,

- 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, and 195 in SEQ ID NO: 1 or 2, if the number of the at least or exactly or at most 5 amino acid residues so permit – if the number of the at least or exactly or at most 5 amino acids is higher than 5, the N-terminal first residue will not be higher numbered than $N-L+1$, where N is the number of amino acid residues of the reference sequence and L is the number of amino acids defined for option b. For instance, if the number of the contiguous amino acid residues defined in option b is exactly 30 and the sequence in question is SEQ ID NO: 1, the N-terminal first residue can hence not be higher numbered than $199-30+1 = 170$, meaning that the 30 amino acid residues in that case will be constituted by amino acid residues 170-199 of SEQ ID NO: 1.
- 15 In the embodiments defined by option b) above, the polypeptide of the invention is also one that has at least or exactly or at most 5 contiguous amino acid residues defined for option b) above and also has its N-terminal amino acid residue corresponding to any one of amino acid residues 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510 and 511, 512, 513, 514, and 515 in SEQ ID NO: 2, if the number of the at least or exactly or at most 5 amino acid residues so permit – if the number of the at least or exactly or at most 5 amino acids is higher than 5, the N-terminal first residue will not be higher numbered than $N-L+1$, where N is the number of amino acid residues of the reference

sequence and L is the number of amino acids defined for option b. For instance, if the number of the contiguous amino acid residues defined in option b is exactly 30 and the sequence in question is SEQ ID NO: 2, the N-terminal first residue can hence not be higher numbered than $519-30+1 = 490$, meaning that the 30 amino acid residues in that case will be constituted by amino acid residues 490-519 of SEQ ID NO: 2.

The polypeptide of the invention is in certain embodiments also fused or conjugated to an immunogenic carrier molecule; or, phrased otherwise, the polypeptide of the invention also includes such an immunogenic carrier molecule in addition to the material derived from SEQ ID NO: 1 or 2. The immunogenic carrier molecule is a typically polypeptide that induces T-helper lymphocyte responses in a majority of humans, such as immunogenic carrier proteins selected from the group consisting of keyhole limpet hemocyanin or a fragment thereof, tetanus toxoid or a fragment thereof, diphtheria toxoid or a fragment thereof. Other suitable carrier molecules are discussed infra. One further fusion partner, which is preferably incorporated is a "His tag", i.e. a stretch of amino acids, which is rich or only consists of histidyl residues so as to facilitate protein purification.

In preferred embodiments, the polypeptide of the invention detailed above is capable of inducing an adaptive immune response against the polypeptide in a mammal, in particular in a human being. Preferably, the adaptive immune response is a protective adaptive immune response against infection with *S. aureus*, in particular multi-resistant *S. aureus*. The polypeptide may in these cases induce a humeral and/or a cellular immune response.

Epitopes

SEQ ID NOs: 1 and 2 include antigenic determinants (epitopes) that are as such recognized by antibodies and/or when bound to MHC molecules by T-cell receptors. For the purposes of the present invention, B-cell epitopes (i.e. antibody binding epitopes) are of particular relevance.

It is relatively uncomplicated to identify linear B-cell epitopes – one very simple approach entails that antibodies raised against *S. aureus* or *S. aureus* derived proteins disclosed herein are tested for binding to overlapping oligomeric peptides derived from SEQ ID NO: 1 or 2. Thereby, the regions of the *S. aureus* polypeptide which are responsible for or contribute to binding to the antibodies can be identified.

Alternatively, or additionally, one can produce mutated versions of the polypeptides of the invention, e.g. version where each single non-alanine residue in SEQ ID NO: 1 or 2 are point mutated to alanine – this method also assists in identifying complex assembled B-cell

epitopes; this is the case when binding of the same antibody is modified by exchanging amino acids in different areas of the full-length polypeptide.

Also, in silico methods for B-cell epitope prediction can be employed: useful state-of-the-art systems for β -turn prediction is provided in Petersen B et al. (November 2010), Plos One
5 **5**(11): e15079; prediction of linear B-cell epitopes, cf.: Larsen J E P et al. (April 2006), Immunome Research, **2**:2; prediction of solvent exposed amino acids: Petersen B et al (July 2009), BMC Structural Biology, **9**:51.

The nucleic acid fragments of the invention

The nucleic acid fragment of the invention referred to above is preferably is a DNA fragment
10 (such as SEQ ID NOs: 3 and 4) or an RNA fragment (such as SEQ ID NOs 5 or 6).

The nucleic acid fragment of the invention typically consists of at least or exactly or at most at least or exactly or at most 11, such as at least or exactly or at most 12, at least or exactly or at most 13, at least or exactly or at most 14, at least or exactly or at most 15, at least or exactly or at most 16, at least or exactly or at most 17 at least or exactly or at most 18, at
15 least or exactly or at most 19, at least or exactly or at most 20, at least or exactly or at most 21, at least or exactly or at most 22, at least or exactly or at most 23, at least or exactly or at most 24, at least or exactly or at most 25, at least or exactly or at most 26, at least or exactly or at most 27, at least or exactly or at most 28, at least or exactly or at most 29, at least or exactly or at most 30, at least or exactly or at most 31, at least or exactly or at most
20 32, at least or exactly or at most 33, at least or exactly or at most 34, at least or exactly or at most 35, at least or exactly or at most 36, at least or exactly or at most 37, at least or exactly or at most 38, at least or exactly or at most 39, at least or exactly or at most 40, at least or exactly or at most 41, at least or exactly or at most 42, at least or exactly or at most 43, at least or exactly or at most 44, at least or exactly or at most 45, at least or exactly or at most 46, at least or exactly or at most 47, at least or exactly or at most 48, at least or exactly or at most 49, at least or exactly or at most 50, at least or exactly or at most 51, at least or exactly or at most 52, at least or exactly or at most 53, at least or exactly or at most 54, at least or exactly or at most 55, at least or exactly or at most 56, at least or exactly or at most 57, at least or exactly or at most 58, at least or exactly or at most 59, at least or exactly or at most 60, at least or exactly or at most 61, at least or exactly or at most 62, at least or exactly or at most 63, at least or exactly or at most 64, at least or exactly or at most 65, at least or exactly or at most 66, at least or exactly or at most 67, at least or exactly or at most 68, at least or exactly or at most 69, at least or exactly or at most 70, at least or exactly or at most 71, at least or exactly or at most 72, at least or exactly or at most 73, at
35 least or exactly or at most 74, at least or exactly or at most 75, at least or exactly or at most

[illegible]

[illegible]

[illegible]

[illegible]

most 513, at least or exactly or at most 514, at least or exactly or at most 515, at least or exactly or at most 516, at least or exactly or at most 517, at least or exactly or at most 518, at least or exactly or at most 519, at least or exactly or at most 520, at least or exactly or at most 521, at least or exactly or at most 522, at least or exactly or at most 523, at least or exactly or at most 524, at least or exactly or at most 525, at least or exactly or at most 526, at least or exactly or at most 527, at least or exactly or at most 528, at least or exactly or at most 529, at least or exactly or at most 530, at least or exactly or at most 531, at least or exactly or at most 532, at least or exactly or at most 533, at least or exactly or at most 534, at least or exactly or at most 535, at least or exactly or at most 536, at least or exactly or at most 537, at least or exactly or at most 538, at least or exactly or at most 539, at least or exactly or at most 540, at least or exactly or at most 541, at least or exactly or at most 542, at least or exactly or at most 543, at least or exactly or at most 544, at least or exactly or at most 545, at least or exactly or at most 546, at least or exactly or at most 547, at least or exactly or at most 548, at least or exactly or at most 549, at least or exactly or at most 550, at least or exactly or at most 551, at least or exactly or at most 552, at least or exactly or at most 553, at least or exactly or at most 554, at least or exactly or at most 555, at least or exactly or at most 556, at least or exactly or at most 557, at least or exactly or at most 558, at least or exactly or at most 559, at least or exactly or at most 560, at least or exactly or at most 561, at least or exactly or at most 562, at least or exactly or at most 563, at least or exactly or at most 564, at least or exactly or at most 565, at least or exactly or at most 566, at least or exactly or at most 567, at least or exactly or at most 568, at least or exactly or at most 569, at least or exactly or at most 570, at least or exactly or at most 571, at least or exactly or at most 572, at least or exactly or at most 573, at least or exactly or at most 574, at least or exactly or at most 575, at least or exactly or at most 576, at least or exactly or at most 577, at least or exactly or at most 578, at least or exactly or at most 579, at least or exactly or at most 580, at least or exactly or at most 581, at least or exactly or at most 582, at least or exactly or at most 583, at least or exactly or at most 584, at least or exactly or at most 585, at least or exactly or at most 586, at least or exactly or at most 587, at least or exactly or at most 588, at least or exactly or at most 589, at least or exactly or at most 590, at least or exactly or at most 591, at least or exactly or at most 592, at least or exactly or at most 593, at least or exactly or at most 594, at least or exactly or at most 595, at least or exactly or at most 596, at least or exactly or at most 597, at least or exactly or at most 598, at least or exactly or at most 599 consecutive nucleotides in the part of the reading frame beginning with residue 1 of SEQ ID NO: 3, 4, 5, or 6 (i.e. that encodes amino acids).

The nucleic acid fragment of the invention can also consist of at least or exactly or at most 600, at least or exactly or at most 601, at least or exactly or at most 602, at least or exactly or at most 603, at least or exactly or at most 604, at least or exactly or at most 605, at least or exactly or at most 606, at least or exactly or at most 607, at least or exactly or at most

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

1510, at least or exactly or at most 1511, at least or exactly or at most 1512, at least or exactly or at most 1513, at least or exactly or at most 1514, at least or exactly or at most 1515, at least or exactly or at most 1516, at least or exactly or at most 1517, at least or exactly or at most 1518, at least or exactly or at most 1519, at least or exactly or at most
5 1520, at least or exactly or at most 1521, at least or exactly or at most 1522, at least or exactly or at most 1523, at least or exactly or at most 1524, at least or exactly or at most 1525, at least or exactly or at most 1526, at least or exactly or at most 1527, at least or exactly or at most 1528, at least or exactly or at most 1529, at least or exactly or at most 1530, at least or exactly or at most 1531, at least or exactly or at most 1532, at least or
10 exactly or at most 1533, at least or exactly or at most 1534, at least or exactly or at most 1535, at least or exactly or at most 1536, at least or exactly or at most 1537, at least or exactly or at most 1538, at least or exactly or at most 1539, at least or exactly or at most 1540, at least or exactly or at most 1541, at least or exactly or at most 1542, at least or exactly or at most 1543, at least or exactly or at most 1544, at least or exactly or at most
15 1545, at least or exactly or at most 1546, at least or exactly or at most 1547, at least or exactly or at most 1548, at least or exactly or at most 1549, at least or exactly or at most 1550, at least or exactly or at most 1551, at least or exactly or at most 1552, at least or exactly or at most 1553, at least or exactly or at most 1554, at least or exactly or at most 1555, at least or exactly or at most 1556, at least or exactly or at most 1557, at least or
20 exactly or at most 1558, and at least or exactly or at most 1559 consecutive nucleotides in the part of SEQ ID NO: 4 or 6 that encodes amino acids in the reading frame starting with residue 1.

The nucleic acid fragment of the invention discussed above typically has a sequence identity with the nucleotide sequence defined for i) or ii) above, which is at least 65%, such as at
25 least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.

The nucleic acid fragment of the invention discussed above may also have a sequence identity with the nucleotide sequence defined for iii) above, which is at least 65%, such as at
30 least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.

The nucleic acid fragment of the invention described above comprises in certain embodiments 1 or 2 distinct nucleic acid sequences each encoding a polypeptide of the invention, where
35 each of said distinct nucleic acid sequences encodes at least or exactly or at most one immunogenic amino acid sequence present in or derived from SEQ ID NO: 1 or 2 and wherein

said distinct nucleic acid sequences together encode immunogenic amino acid sequences present in or derived from one or both of SEQ ID NOs 1 and 2. In other words, such a nucleic acid fragment encodes several polypeptides of the invention. In some embodiments, the nucleic acid sequences are expressed as separate encoded proteins and in other
5 embodiments as "pearls on a string", i.e. fused proteins.

It will be understood that the nucleic acid fragments of the invention may be used for production, carrier and vaccine purposes – the latter will require that the sequences are included in expression vectors that may lead to production of immunogenic proteins in the host animal receiving the vector.

10 The vectors of the invention

Vectors of the invention fall into several categories discussed *infra*. One preferred vector of the invention comprises in operable linkage and in the 5'-3' direction, an expression control region comprising an enhancer/promoter for driving expression of the nucleic acid fragment defined for option i) above, optionally a signal peptide coding sequence, a nucleotide
15 sequence defined for option i), and optionally a terminator. Hence, such a vector constitutes an expression vector useful for effecting production in cells of the polypeptide of the invention. Since the polypeptides of the invention are bacterial of origin, recombinant production is conveniently effected in bacterial host cells, so here it is preferred that the expression control region drives expression in prokaryotic cell such as a bacterium, e.g. in E
20 coli. However, if the vector is to drive expression in mammalian cell (as would be the case for a DNA vaccine vector), the expression control region should be adapted to this particular use.

At any rate, certain vectors of the invention are capable of autonomous replication.

Also, the vector of the invention may be one that is capable of being integrated into the genome of a host cell – this is particularly useful if the vector is use in the production of
25 stably transformed cells, where the progeny will also include the genetic information introduced via the vector. Alternatively, vectors incapable of being integrated into the genome of a mammalian host cell are useful in e.g. DNA vaccination and other nucleic acid vaccination techniques.

Typically, the vector of the invention is selected from the group consisting of a virus, such as
30 an attenuated virus (which may in itself be useful as a vaccine agent), a bacteriophage, a plasmid, a minichromosome, and a cosmid.

Particularly interesting vectors are viral vectors (in particular those useful as vaccine agents). These may be selected from the group consisting of a retrovirus vector, such as a lentivirus vector, an adenovirus vector, an adeno-associated virus vector, and a pox virus vector. Certain pox virus vectors are preferred, in particular vaccinia virus vectors. A particularly
5 preferred vaccinia virus vector is a modified vaccinia Ankara (MVA) vector.

A more detailed discussion of vectors of the invention is provided in the following:

Polypeptides of the invention may be encoded by a nucleic acid molecule comprised in a vector. A nucleic acid sequence can be "heterologous," which means that it is in a context foreign to the cell in which the vector is being introduced, which includes a sequence
10 homologous to a sequence in the cell but in a position within the host cell where it is ordinarily not found. Vectors include naked DNAs, RNAs, plasmids, cosmids, viruses (bacteriophage, animal viruses, and plant viruses), and artificial chromosomes (e.g., YACs). One of skill in the art would be well equipped to construct a vector through standard recombinant techniques (for example Sambrook et al, 2001; Ausubel et al, 1996, both
15 incorporated herein by reference). In addition to encoding the polypeptides of this invention, a vector of the present invention may encode polypeptide sequences such as a tag or immunogenicity enhancing peptide (e.g. an immunogenic carrier or a fusion partner that stimulates the immune system, such as a cytokine or active fragment thereof). Useful vectors encoding such fusion proteins include pIN vectors (Inouye et al, 1985), vectors
20 encoding a stretch of histidines, and pGEX vectors, for use in generating glutathione S-transferase (GST) soluble fusion proteins for later purification and separation or cleavage.

Vectors of the invention may be used in a host cell to produce a polypeptide of the invention that may subsequently be purified for administration to a subject or the vector may be purified for direct administration to a subject for expression of the protein in the subject (as
25 is the case when administering a nucleic acid vaccine).

Expression vectors can contain a variety of "control sequences," which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operably linked coding sequence in a particular host organism. In addition to control sequences that govern transcription and translation, vectors and expression vectors may contain nucleic acid
30 sequences that serve other functions as well and are described *infra*.

1. Promoters and Enhancers

A "promoter" is a control sequence. The promoter is typically a region of a nucleic acid sequence at which initiation and rate of transcription are controlled. It may contain genetic

elements at which regulatory proteins and molecules may bind such as RNA polymerase and other transcription factors. The phrases "operatively positioned," "operatively linked," "under control," and "under transcriptional control" mean that a promoter is in a correct functional location and/or orientation in relation to a nucleic acid sequence to control transcriptional initiation and expression of that sequence. A promoter may or may not be used in conjunction with an "enhancer," which refers to a cis-acting regulatory sequence involved in the transcriptional activation of a nucleic acid sequence.

A promoter may be one naturally associated with a gene or sequence, as may be obtained by isolating the 5' non-coding sequences located upstream of the coding segment or exon. Such a promoter can be referred to as "endogenous." Similarly, an enhancer may be one naturally associated with a nucleic acid sequence, located either downstream or upstream of that sequence. Alternatively, certain advantages will be gained by positioning the coding nucleic acid segment under the control of a recombinant or heterologous promoter, which refers to a promoter that is not normally associated with a nucleic acid sequence in its natural environment. A recombinant or heterologous enhancer refers also to an enhancer not normally associated with a nucleic acid sequence in its natural state. Such promoters or enhancers may include promoters or enhancers of other genes, and promoters or enhancers isolated from any other prokaryotic, viral, or eukaryotic cell, and promoters or enhancers not "naturally occurring," i.e., containing different elements of different transcriptional regulatory regions, and/or mutations that alter expression. In addition to producing nucleic acid sequences of promoters and enhancers synthetically, sequences may be produced using recombinant cloning and/or nucleic acid amplification technology, including PCR™, in connection with the compositions disclosed herein (see U.S. Patent 4,683,202, U.S. Patent 5,928,906, each incorporated herein by reference).

Naturally, it may be important to employ a promoter and/or enhancer that effectively direct(s) the expression of the DNA segment in the cell type or organism chosen for expression. Those of skill in the art of molecular biology generally know the use of promoters, enhancers, and cell type combinations for protein expression (see Sambrook et al, 2001, incorporated herein by reference). The promoters employed may be constitutive, tissue-specific, or inducible and in certain embodiments may direct high level expression of the introduced DNA segment under specified conditions, such as large-scale production of recombinant proteins or peptides.

Examples of inducible elements, which are regions of a nucleic acid sequence that can be activated in response to a specific stimulus, include but are not limited to Immunoglobulin Heavy Chain, Immunoglobulin Light Chain, T Cell Receptor, HLA DQ α and/or DQ β , β -Interferon, Interleukin-2, Interleukin-2 Receptor, MHC Class II 5, MHC Class II HLA-DR α , β -

Actin, Muscle Creatine Kinase (MCK), Prealbumin (Transthyretin), Elastase I, Metallothionein (MTII), Collagenase, Albumin, α -Fetoprotein, γ -Globin, β -Globin, c-fos, c-HA-ras, Insulin, Neural Cell Adhesion Molecule (NCAM), dI-Antitrypsin, H2B (TH2B) Histone, Mouse and/or Type I Collagen, Glucose-Regulated Proteins (GRP94 and GRP78), Rat Growth Hormone, Human Serum Amyloid A (SAA), Troponin I (TN I), Platelet-Derived Growth Factor (PDGF), Duchenne Muscular Dystrophy, SV40, Polyoma, Retroviruses, Papilloma Virus, Hepatitis B Virus, Human Immunodeficiency Virus, Cytomegalovirus (CMV) IE, and Gibbon Ape Leukemia Virus.

Inducible Elements include, but are not limited to MT II - Phorbol Ester (TFA)/Heavy metals; MMTV (mouse mammary tumor virus) - Glucocorticoids; β -Interferon - poly(rl)x/poly(rc); Adenovirus 5 E2 - EIA; Collagenase - Phorbol Ester (TPA); Stromelysin - Phorbol Ester (TPA); SV40 - Phorbol Ester (TPA); Murine MX Gene - Interferon, Newcastle Disease Virus; GRP78 Gene - A23187; α -2-Macroglobulin - IL-6; Vimentin - Serum; MHC Class I Gene H-2kb - Interferon; HSP70 - E1A/SV40 Large T Antigen; Proliferin - Phorbol Ester/TPA; Tumor Necrosis Factor - PMA; and Thyroid Stimulating Hormone Gene - Thyroid Hormone.

Also contemplated as useful in the present invention are the dectin-1 and dectin-2 promoters. Additionally any promoter/enhancer combination (as per the Eukaryotic Promoter Data Base EPDB) could also be used to drive expression of structural genes encoding oligosaccharide processing enzymes, protein folding accessory proteins, selectable marker proteins or a heterologous protein of interest.

The particular promoter that is employed to control the expression of peptide or protein encoding polynucleotide of the invention is not believed to be critical, so long as it is capable of expressing the polynucleotide in a targeted cell, preferably a bacterial cell. Where a human cell is targeted, it is preferable to position the polynucleotide coding region adjacent to and under the control of a promoter that is capable of being expressed in a human cell. Generally speaking, such a promoter might include either a bacterial, human or viral promoter.

In various embodiments, the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter, and the Rous sarcoma virus long terminal repeat can be used to obtain high level expression of a related polynucleotide to this invention. The use of other viral or mammalian cellular or bacterial phage promoters, which are well known in the art, to achieve expression of polynucleotides is contemplated as well.

In embodiments in which a vector is administered to a subject for expression of the protein, it is contemplated that a desirable promoter for use with the vector is one that is not down-regulated by cytokines or one that is strong enough that even if down-regulated, it produces

an effective amount of the protein/polypeptide of the current invention in a subject to elicit an immune response. Non-limiting examples of these are CMV IE and RSV LTR. In other embodiments, a promoter that is up-regulated in the presence of cytokines is employed. The MHC I promoter increases expression in the presence of IFN- γ .

- 5 Tissue specific promoters can be used, particularly if expression is in cells in which expression of an antigen is desirable, such as dendritic cells or macrophages. The mammalian MHC I and MHC II promoters are examples of such tissue-specific promoters. 2. Initiation Signals and Internal Ribosome Binding Sites (IRES)

A specific initiation signal also may be required for efficient translation of coding sequences.

- 10 These signals include the ATG initiation codon or adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, may need to be provided. One of ordinary skill in the art would readily be capable of determining this and providing the necessary signals. It is well known that the initiation codon must be "in-frame" with the reading frame of the desired coding sequence to ensure translation of the entire insert. The
15 exogenous translational control signals and initiation codons can be either natural or synthetic and may be operable in bacteria or mammalian cells. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements.

- In certain embodiments of the invention, the use of internal ribosome entry sites (IRES) elements are used to create multigene, or polycistronic, messages. IRES elements are able to
20 bypass the ribosome scanning model of 5' methylated Cap dependent translation and begin translation at internal sites. IRES elements from two members of the picornavirus family (polio and encephalomyocarditis) have been described, as well an IRES from a mammalian message. IRES elements can be linked to heterologous open reading frames. Multiple open reading frames can be transcribed together, each separated by an IRES, creating
25 polycistronic messages. By virtue of the IRES element, each open reading frame is accessible to ribosomes for efficient translation. Multiple genes can be efficiently expressed using a single promoter/enhancer to transcribe a single message (see U.S. Patents 5,925,565 and 5,935,819, herein incorporated by reference).

2. Multiple Cloning Sites

- 30 Vectors can include a multiple cloning site (MCS), which is a nucleic acid region that contains multiple restriction enzyme sites, any of which can be used in conjunction with standard recombinant technology to digest the vector. Frequently, a vector is linearized or fragmented using a restriction enzyme that cuts within the MCS to enable exogenous sequences to be

ligated to the vector. Techniques involving restriction enzymes and ligation reactions are well known to those of skill in the art of recombinant technology.

3. Splicing Sites

Most transcribed eukaryotic RNA molecules will undergo RNA splicing to remove introns from the primary transcripts. If relevant in the context of vectors of the present invention, vectors containing genomic eukaryotic sequences may require donor and/or acceptor splicing sites to ensure proper processing of the transcript for protein expression.

4. Termination Signals

The vectors or constructs of the present invention will generally comprise at least one termination signal. A "termination signal" or "terminator" is comprised of the DNA sequences involved in specific termination of an RNA transcript by an RNA polymerase. Thus, in certain embodiments a termination signal that ends the production of an RNA transcript is contemplated. A terminator may be necessary in vivo to achieve desirable message levels.

In eukaryotic systems, the terminator region may also comprise specific DNA sequences that permit site-specific cleavage of the new transcript so as to expose a polyadenylation site. This signals a specialized endogenous polymerase to add a stretch of about 200 A residues (poly A) to the 3' end of the transcript. RNA molecules modified with this polyA tail appear to more stable and are translated more efficiently. Thus, in other embodiments involving eukaryotes, it is preferred that that terminator comprises a signal for the cleavage of the RNA, and it is more preferred that the terminator signal promotes polyadenylation of the message.

Terminators contemplated for use in the invention include any known terminator of transcription described herein or known to one of ordinary skill in the art, including but not limited to, for example, the bovine growth hormone terminator or viral termination sequences, such as the SV40 terminator. In certain embodiments, the termination signal may be a lack of transcribable or translatable sequence, such as due to a sequence truncation.

5. Polyadenylation Signals

In expression, particularly eukaryotic expression (as is relevant in nucleic acid vaccination), one will typically include a polyadenylation signal to effect proper polyadenylation of the transcript. The nature of the polyadenylation signal is not believed to be crucial to the successful practice of the invention, and/or any such sequence may be employed. Preferred

embodiments include the SV40 polyadenylation signal and/or the bovine growth hormone polyadenylation signal, convenient and/or known to function well in various target cells. Polyadenylation may increase the stability of the transcript or may facilitate cytoplasmic transport.

5 **6. Origins of Replication**

In order to propagate a vector in a host cell, it may contain one or more origins of replication sites (often termed "on"), which is a specific nucleic acid sequence at which replication is initiated. Alternatively an autonomously replicating sequence (ARS) can be employed if the host cell is yeast.

10 **7. Selectable and Screenable Markers**

In certain embodiments of the invention, cells containing a nucleic acid construct of the present invention may be identified in vitro or in vivo by encoding a screenable or selectable marker in the expression vector. When transcribed and translated, a marker confers an identifiable change to the cell permitting easy identification of cells containing the expression
15 vector. Generally, a selectable marker is one that confers a property that allows for selection. A positive selectable marker is one in which the presence of the marker allows for its selection, while a negative selectable marker is one in which its presence prevents its selection. An example of a positive selectable marker is a drug resistance marker.

Usually the inclusion of a drug selection marker aids in the cloning and identification of
20 transformants, for example, markers that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin or histidinol are useful selectable markers. In addition to markers conferring a phenotype that allows for the discrimination of transformants based on the implementation of conditions, other types of markers including screenable markers such as GFP for colorimetric analysis. Alternatively, screenable enzymes such as herpes simplex
25 virus thymidine kinase (tk) or chloramphenicol acetyltransferase (CAT) may be utilized. One of skill in the art would also know how to employ immunologic markers that can be used in conjunction with FACS analysis. The marker used is not believed to be important, so long as it is capable of being expressed simultaneously with the nucleic acid encoding a protein of the invention. Further examples of selectable and screenable markers are well known to one of
30 skill in the art.

The transformed cells of the invention

Transformed cells of the invention are useful as organisms for producing the polypeptide of the invention, but also as simple "containers" of nucleic acids and vectors of the invention.

- 5 Certain transformed cells of the invention are capable of replicating the nucleic acid fragment defined for option i) of the second aspect of the invention. Preferred transformed cells of the invention are capable of expressing the nucleic acid fragment defined for option i).

For recombinant production it is convenient, but not a prerequisite that the transformed cell according is prokaryotic, such as a bacterium, but generally both prokaryotic cells and eukaryotic cells may be used.

- 10 Suitable prokaryotic cells are bacterial cells selected from the group consisting of *Escherichia* (such as *E. coli*.), *Bacillus* [e.g. *Bacillus subtilis*], *Salmonella*, and *Mycobacterium* [preferably non-pathogenic, e.g. *M. bovis* BCG].

- 15 Eukaryotic cells can be in the form of yeasts (such as *Saccharomyces cerevisiae*) and protozoans. Alternatively, the transformed eukaryotic cells are derived from a multicellular organism such as a fungus, an insect cell, a plant cell, or a mammalian cell.

- For production purposes, it is advantageous that the transformed cell of the invention is stably transformed by having the nucleic acid defined above for option i) stably integrated into its genome, and in certain embodiments it is also preferred that the transformed cell secretes or carries on its surface the polypeptide of the invention, since this facilitates
20 recovery of the polypeptides produced. A particular version of this embodiment is one where the transformed cell is a bacterium and secretion of the polypeptide of the invention is into the periplasmic space.

- As noted above, stably transformed cells are preferred – these i.a. allows that cell lines comprised of transformed cells as defined herein may be established – such cell lines are
25 particularly preferred aspects of the invention.

Further details on cells and cell lines are presented in the following:

Suitable cells for recombinant nucleic acid expression of the nucleic acid fragments of the present invention are prokaryotes and eukaryotes. Examples of prokaryotic cells include *E. coli*; members of the *Staphylococcus* genus, such as *S. epidermidis*; members of the

Lactobacillus genus, such as *L. plantarum*; members of the *Lactococcus* genus, such as *L. lactis*; members of the *Bacillus* genus, such as *B. subtilis*; members of the *Corynebacterium* genus such as *C. glutamicum*; and members of the *Pseudomonas* genus such as *Ps. fluorescens*. Examples of eukaryotic cells include mammalian cells; insect cells; yeast cells
5 such as members of the *Saccharomyces* genus (e.g. *S. cerevisiae*), members of the *Pichia* genus (e.g. *P. pastoris*), members of the *Hansenula* genus (e.g. *H. polymorpha*), members of the *Kluyveromyces* genus (e.g. *K. lactis* or *K. fragilis*) and members of the *Schizosaccharomyces* genus (e.g. *S. pombe*).

Techniques for recombinant gene production, introduction into a cell, and recombinant gene
10 expression are well known in the art. Examples of such techniques are provided in references such as Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-2002, and Sambrook et al., Molecular Cloning, A Laboratory Manual, 2 nd Edition, Cold Spring Harbor Laboratory Press, 1989.

As used herein, the terms "cell," "cell line," and "cell culture" may be used interchangeably.
15 All of these terms also include their progeny, which is any and all subsequent generations. It is understood that all progeny may not be identical due to deliberate or inadvertent mutations. In the context of expressing a heterologous nucleic acid sequence, "host cell" refers to a prokaryotic or eukaryotic cell, and it includes any transformable organism that is capable of replicating a vector or expressing a heterologous gene encoded by a vector. A host
20 cell can, and has been, used as a recipient for vectors or viruses. A host cell may be "transfected" or "transformed," which refers to a process by which exogenous nucleic acid, such as a recombinant protein-encoding sequence, is transferred or introduced into the host cell. A transformed cell includes the primary subject cell and its progeny.

Host cells may be derived from prokaryotes or eukaryotes, including bacteria, yeast cells,
25 insect cells, and mammalian cells for replication of the vector or expression of part or all of the nucleic acid sequence(s). Numerous cell lines and cultures are available for use as a host cell, and they can be obtained through the American Type Culture Collection (ATCC), which is an organization that serves as an archive for living cultures and genetic materials (www.atcc.org) or from other depository institutions such as Deutsche Sammlung vor
30 Mikroorganismen und Zellkulturen (DSMZ). An appropriate host can be determined by one of skill in the art based on the vector backbone and the desired result. A plasmid or cosmid, for example, can be introduced into a prokaryote host cell for replication of many vectors or expression of encoded proteins. Bacterial cells used as host cells for vector replication and/or
35 expression include *Staphylococcus* strains, DH5 α , JMI 09, and KC8, as well as a number of commercially available bacterial hosts such as SURE(R) Competent Cells and SOLOP ACK(TM) Gold Cells (STRATAGENE®, La Jolla, CA). Alternatively, bacterial cells such as *E. coli* LE392

could be used as host cells for phage viruses. Appropriate yeast cells include *Saccharomyces cerevisiae*, *Saccharomyces pombe*, and *Pichia pastoris*.

Examples of eukaryotic host cells for replication and/or expression of a vector include HeLa, NIH3T3, Jurkat, 293, Cos, CHO, Saos, and PC12. Many host cells from various cell types and organisms are available and would be known to one of skill in the art. Similarly, a viral vector may be used in conjunction with either a eukaryotic or prokaryotic host cell, particularly one that is permissive for replication or expression of the vector.

Some vectors may employ control sequences that allow it to be replicated and/or expressed in both prokaryotic and eukaryotic cells. One of skill in the art would further understand the conditions under which to incubate all of the above described host cells to maintain them and to permit replication of a vector. Also understood and known are techniques and conditions that would allow large-scale production of vectors, as well as production of the nucleic acids encoded by vectors and their cognate polypeptides, proteins, or peptides.

Expression Systems

Numerous expression systems exist that comprise at least a part or all of the compositions discussed above. Prokaryote- and/or eukaryote-based systems can be employed for use with the present invention to produce nucleic acid sequences, or their cognate polypeptides, proteins and peptides. Many such systems are commercially and widely available.

The insect cell/baculovirus system can produce a high level of protein expression of a heterologous nucleic acid segment, such as described in U.S. Patents 5,871,986, 4,879,236, both herein incorporated by reference, and which can be bought, for example, under the name MAXBAC® 2.0 from INVITROGEN® and BACPACK™ Baculovirus expression system from CLONTECH®

In addition to the disclosed expression systems of the invention, other examples of expression systems include STRATAGENE®'s COMPLETE CONTROL™ Inducible Mammalian Expression System, which involves a synthetic ecdysone-inducible receptor, or its pET Expression System, an E. coli expression system. Another example of an inducible expression system is available from INVITROGEN®, which carries the T-REX™ (tetracycline-regulated expression) System, an inducible mammalian expression system that uses the full-length CMV promoter. INVITROGEN® also provides a yeast expression system called the Pichia methanolica Expression System, which is designed for high-level production of recombinant proteins in the methylotrophic yeast Pichia methanolica. One of skill in the art would know

how to express a vector, such as an expression construct, to produce a nucleic acid sequence or its cognate polypeptide, protein, or peptide.

Amplification of Nucleic Acids

5 Nucleic acids used as a template for amplification may be isolated from cells, tissues or other samples according to standard methodologies (Sambrook et al, 2001). In certain embodiments, analysis is performed on whole cell or tissue homogenates or biological fluid samples without substantial purification of the template nucleic acid. The nucleic acid may be genomic DNA or fractionated or whole cell RNA. Where RNA is used, it may be desired to first convert the RNA to a complementary DNA.

10 The term "primer," as used herein, is meant to encompass any nucleic acid that is capable of priming the synthesis of a nascent nucleic acid in a template-dependent process. Typically, primers are oligonucleotides from ten to twenty and/or thirty base pairs in length, but longer sequences can be employed. Primers may be provided in double-stranded and/or single-stranded form, although the single-stranded form is preferred.

15 Pairs of primers designed to selectively hybridize to nucleic acids corresponding to sequences of genes identified herein are contacted with the template nucleic acid under conditions that permit selective hybridization. Depending upon the desired application, high stringency hybridization conditions may be selected that will only allow hybridization to sequences that are completely complementary to the primers. In other embodiments, hybridization may
20 occur under reduced stringency to allow for amplification of nucleic acids containing one or more mismatches with the primer sequences. Once hybridized, the template-primer complex is contacted with one or more enzymes that facilitate template-dependent nucleic acid synthesis. Multiple rounds of amplification, also referred to as "cycles," are conducted until a sufficient amount of amplification product is produced.

25 The amplification product may be detected or quantified. In certain applications, the detection may be performed by visual means. Alternatively, the detection may involve indirect identification of the product via chemiluminescence, radioactive scintigraphy of incorporated radiolabel or fluorescent label or even via a system using electrical and/or thermal impulse signals.

30 A number of template dependent processes are available to amplify the oligonucleotide sequences present in a given template sample. One of the best known amplification methods is the polymerase chain reaction (referred to as PCR(TM)) which is described in detail in U.S.

Patents 4,683,195, 4,683,202 and 4,800,159, and in Innis et al., 1988, each of which is incorporated herein by reference in their entirety.

Alternative methods for amplification of target nucleic acid sequences that may be used in the practice of the present invention are disclosed in U.S. Patents 5,843,650, 5,846,709, 5,846,783, 5,849,546, 5,849,497, 5,849,547, 5,858,652, 5,866,366, 5,916,776, 5,922,574, 5,928,905, 5,928,906, 5,932,451, 5,935,825, 5,939,291 and 5,942,391, GB Application No. 2 202 328, and in PCT Application No. PCT/US89/01025, each of which is incorporated herein by reference in its entirety.

Methods of Gene Transfer

Suitable methods for nucleic acid delivery to effect expression of compositions of the present invention are believed to include virtually any method by which a nucleic acid (e.g., DNA, including viral and nonviral vectors) can be introduced into a cell, a tissue or an organism, as described herein or as would be known to one of ordinary skill in the art. Such methods include, but are not limited to, direct delivery of DNA such as by injection (U.S. Patents 5,994,624, 5,981,274, 5,945,100, 5,780,448, 5,736,524, 5,702,932, 5,656,610, 5,589,466 and 5,580,859, each incorporated herein by reference), including microinjection (U.S. Patent 5,789,215, incorporated herein by reference); by electroporation (U.S. Patent No. 5,384,253, incorporated herein by reference); by calcium phosphate precipitation; by using DEAE dextran followed by polyethylene glycol (Gopal, 1985); by direct sonic loading; by liposome mediated transfection; by microprojectile bombardment (PCT Application Nos. WO 94/09699 and 95/06128; U.S. Patents 5,610,042; 5,322,783 5,563,055, 5,550,318, 5,538,877 and 5,538,880, and each incorporated herein by reference); by agitation with silicon carbide fibers (U.S. Patents 5,302,523 and 5,464,765, each incorporated herein by reference); by Agrobacterium mediated transformation (U.S. Patents 5,591,616 and 5,563,055, each incorporated herein by reference); or by PEG mediated transformation of protoplasts (U.S. Patents 4,684,611 and 4,952,500, each incorporated herein by reference); by desiccation/inhibition mediated DNA uptake. Through the application of techniques such as these, organelle(s), cell(s), tissue(s) or organism(s) may be stably or transiently transformed.

The antibodies of the invention – and their production/isolation

Antibodies directed against the proteins of the invention are useful for affinity chromatography, immunoassays, and for distinguishing/identifying staphylococcus proteins as well as for passive immunisation and therapy.

Antibodies to the proteins of the invention, both polyclonal and monoclonal, may be prepared by conventional methods. In general, the protein is first used to immunize a suitable animal, preferably a mouse, rat, rabbit or goat. Rabbits and goats are preferred for the preparation of polyclonal sera due to the volume of serum obtainable, and the availability of labeled anti-rabbit and anti-goat antibodies. Immunization is generally performed by mixing or emulsifying the protein in saline, preferably in an adjuvant such as Freund's complete adjuvant, and injecting the mixture or emulsion parenterally (generally subcutaneously or intramuscularly). A dose of 50-200 µg/injection is typically sufficient. Immunization is generally boosted 2-6 weeks later with one or more injections of the protein in saline, preferably using Freund's incomplete adjuvant. One may alternatively generate antibodies by *in vitro* immunization using methods known in the art, which for the purposes of this invention is considered equivalent to *in vivo* immunization. Polyclonal antiserum is obtained by bleeding the immunized animal into a glass or plastic container, incubating the blood at 25 C for one hour, followed by incubating at 4 C for 2-18 hours. The serum is recovered by centrifugation (eg. 1,000 g for 10 minutes). About 20-50 ml per bleed may be obtained from rabbits.

Monoclonal antibodies are prepared using the standard method of Kohler & Milstein [Nature (1975) 256 : 495-96], or a modification thereof. Typically, a mouse or rat is immunized as described above. However, rather than bleeding the animal to extract serum, the spleen (and optionally several large lymph nodes) is removed and dissociated into single cells. If desired, the spleen cells may be screened (after removal of nonspecifically adherent cells) by applying a cell suspension to a plate or well coated with the protein antigen. B-cells expressing membrane-bound immunoglobulin specific for the antigen bind to the plate, and are not rinsed away with the rest of the suspension. Resulting B-cells, or all dissociated spleen cells, are then induced to fuse with myeloma cells to form hybridomas, and are cultured in a selective medium (e.g. hypoxanthine, aminopterin, thymidine medium, "HAT"). The resulting hybridomas are plated by limiting dilution, and are assayed for production of antibodies, which bind specifically to the immunizing antigen (and which do not bind to unrelated antigens). The selected MAb-secreting hybridomas are then cultured either *in vitro* (eg. in tissue culture bottles or hollow fiber reactors), or *in vivo* (as ascites in mice).

If desired, the antibodies (whether polyclonal or monoclonal) may be labeled using conventional techniques. Suitable labels include fluorophores, chromophores, radioactive atoms (particularly ³²P and ¹²⁵I), electron-dense reagents, enzymes, and ligands having specific binding partners. Enzymes are typically detected by their activity. For example, horseradish peroxidase is usually detected by its ability to convert 3,3', 5,5'-tetramethylbenzidine (TMB) to a blue pigment, quantifiable with a spectrophotometer. "Specific binding partner" refers to a protein capable of binding a ligand molecule with high

specificity, as for example in the case of an antigen and a monoclonal antibody specific therefor. Other specific binding partners include biotin and avidin or streptavidin, IgG and protein A, and the numerous receptor-ligand couples known in the art. It should be understood that the above description is not meant to categorize the various labels into distinct classes, as the same label may serve in several different modes. For example, ¹¹⁵¹I may serve as a radioactive label or as an electron-dense reagent. HRP may serve as enzyme or as antigen for a MAb. Further, one may combine various labels for desired effect. For example, MAbs and avidin also require labels in the practice of this invention: thus, one might label a MAb with biotin, and detect its presence with avidin labeled with ¹²⁵I, or with an anti-biotin MAb labeled with HRP. Other permutations and possibilities will be readily apparent to those of ordinary skill in the art, and are considered as equivalents within the scope of the instant invention.

According to the invention, the isolated monoclonal antibody or antibody analogue is preferably a monoclonal antibody selected from a multi-domain antibody such as a murine antibody, a chimeric antibody such as a humanized antibody, a fully human antibody, and single-domain antibody of a llama or a camel, or which is an antibody analogue selected from a fragment of an antibody such as an Fab or an F(ab')₂, an scFV; cf. also the definition of the term "antibody" presented above.

Compositions of the invention; vaccines

Pharmaceutical compositions, in particular vaccines, according to the invention may either be prophylactic (ie. to prevent infection) or therapeutic (ie, to treat disease after infection).

Such vaccines comprise immunising antigen(s), immunogen(s), polypeptide(s), protein(s) or nucleic acid(s), usually in combination with "pharmaceutically acceptable carriers", which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition.

In some embodiments of the invention, the pharmaceutical compositions such as vaccines include merely one single antigen, immunogen, polypeptide, protein, nucleic acid or vector of the invention, but in other embodiments, the pharmaceutical compositions comprise "cocktails" of the antigens or of the immunogens or of the polypeptides or of the protein or of the nucleic acids or of the vectors of the invention.

In particularly interesting embodiments, the pharmaceutical composition is an MVA vector mentioned herein, which encodes and can effect expression of at least 2 nucleic acid fragments of the invention.

Another interesting embodiment of a pharmaceutical composition comprises RNA as the active principle, i.e. at least one mRNA encoding a polypeptide of the invention.

An embodiment of a pharmaceutical composition of the invention comprises at least 2 distinct polypeptides of the invention described above, where each of said 2 distinct polypeptides comprises an immunogenic amino acid sequence present in or derived from SEQ ID NO: 1 or 2 and wherein said distinct polypeptides together comprise immunogenic amino acid sequences present in or derived from both SEQ ID NO: 1 and 2.

Another embodiment of the pharmaceutical composition of the invention comprises at least 2 distinct nucleic acid molecules (such as DNA and RNA) each encoding a polypeptide of the invention, where each of said distinct nucleic acid molecules encodes an immunogenic amino acid sequence present in or derived from any one of SEQ ID NOs: 1 or 2 and wherein said at distinct nucleic acid molecules together encode immunogenic amino acid sequences present in or derived from both SEQ ID NO 1 and 2.

Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles.

Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the antigen or immunogen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, H. pylori, etc. pathogen, cf. the description of immunogenic carriers supra.

The pharmaceutical compositions of the invention thus typically contain an immunological adjuvant, which is commonly an aluminium based adjuvant or one of the other adjuvants described in the following:

Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59 (WO 90/14837; Chapter 10 in Vaccine design: the subunit and adjuvant approach, eds. Powell & Newman, Plenum Press 1995), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE (see below), although not required) formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, MA), (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-

MDP (see below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) Ribi adjuvant system (RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphoryl lipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (Detox™); (3) saponin adjuvants such as Stimulon™ (Cambridge Bioscience, Worcester, MA) may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes); (4) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA); (5) cytokines, such as interleukins (eg. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), interferons (eg. gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc.; and (6) other substances that act as immunostimulating agents to enhance the effectiveness of the composition. Alum and MF59™ adjuvants are preferred.

As mentioned above, muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2"-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), etc.

The immunogenic compositions (eg. the immunising antigen or immunogen or polypeptide or protein or nucleic acid, pharmaceutically acceptable carrier, and adjuvant) typically will contain diluents, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles.

Typically, the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect, as discussed above under pharmaceutically acceptable carriers.

Immunogenic compositions used as vaccines comprise an immunologically effective amount of the antigenic or immunogenic polypeptides, as well as any other of the above-mentioned components, as needed. By "immunologically effective amount", it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (eg. nonhuman primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies or generally mount an immune response, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical

situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. However, for the purposes of protein vaccination, the amount administered per immunization is typically in the range between 0.5 µg and 500 mg (however, often not higher than 5,000 µg), and very often in the
5 range between 10 and 200 µg.

The immunogenic compositions are conventionally administered parenterally, eg, by injection, either subcutaneously, intramuscularly, or transdermally/transcutaneously. Additional formulations suitable for other modes of administration include oral and pulmonary formulations, suppositories, and transdermal applications. In the case of nucleic acid
10 vaccination, also the intravenous or intraarterial routes may be applicable.

Dosage treatment may be a single dose schedule or a multiple dose schedule. The vaccine may be administered in conjunction with other immunoregulatory agents.

As an alternative to protein-based vaccines, DNA vaccination (also termed nucleic acid vaccination or gene vaccination) may be used.

15 A further aspect of the invention is as mentioned above the recognition that combination vaccines can be provided, wherein 2 or more antigens disclosed herein are combined to enhance the immune response by the vaccinated animal, including to optimize initial immune response and duration of immunity. For the purposes of this aspect of the invention, multiple antigenic fragments derived from the same, longer protein can also be used, such as the use
20 of a combination of different lengths of polypeptide sequence fragments from one protein.

Thus, embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct (i.e. non-identical) proteinaceous immunogens disclosed herein wherein the first of said immunogens has the amino acid sequence SEQ ID NO: 1 or a variant or fragment thereof disclosed herein, in combination with a non-identical variant or fragment
25 disclosed herein of the polypeptide having the amino acid sequence SEQ ID NO: 1. Alternatively, the two proteinaceous immunogens may be comprised in one single fusion protein. Also, compositions comprising nucleic acids encoding these two distinct proteinaceous immunogens (either as separate nucleic acids encoding one immunogen each or as one single nucleic acid encoding both immunogens or encoding the fusion immunogen)
30 are part of the present invention.

Other embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct proteinaceous immunogens disclosed herein wherein the first of said immunogens has the amino acid sequence SEQ ID NO: 2 or a variant or fragment thereof

disclosed herein, in combination with a non-identical variant or fragment disclosed herein of the polypeptide having the amino acid sequence SEQ ID NO: 2. Also, compositions comprising nucleic acids encoding these two distinct proteinaceous immunogens (either as separate nucleic acids encoding one immunogen each or as one single nucleic acid encoding both immunogens or encoding the fusion immunogen) are part of the present invention.

Still other embodiments of the invention relate to a composition (or the use as a vaccine thereof) comprising 2 distinct proteinaceous immunogens disclosed herein wherein the first of said immunogens has the amino acid sequence SEQ ID NO: 1 or a variant or fragment thereof disclosed herein, in combination with a proteinaceous immunogen that has the amino acid sequence SEQ ID NO: 2 or a variant or fragment thereof disclosed herein. Also, compositions comprising nucleic acids encoding these two distinct proteinaceous immunogens (either as separate nucleic acids encoding one immunogen each or as one single nucleic acid encoding both immunogens or encoding the fusion immunogen) are part of the present invention.

In addition to this, the present invention also relates to immunogenic compositions that include a (poly)peptide of the present invention derived from SEQ ID NO: 1 (i.e. being one of the fragments or sequence variants disclosed herein) or being identical to SEQ ID NO: 1 in combination with any one of the polypeptides disclosed as SEQ ID NOs: 1-19 in WO 2012/136653 or with any one of the fragments and variants of these polypeptides disclosed on pages 9-18 in WO 2012/136653. Further, the present invention relates to immunogenic compositions that include a (poly)peptide of the present invention derived from SEQ ID NO: 2 (i.e. being one of the fragments or sequence variants disclosed herein) or being identical to SEQ ID NO: 2 in combination with any one of the polypeptides disclosed as SEQ ID NOs: 1-19 in WO 2012/136653 or with any one of the fragments or variants of these polypeptides disclosed on pages 9-18 in WO 2012/136653. Also, the present invention relates to immunogenic compositions that include two (poly)peptides of the present invention derived from SEQ ID NO: 1 and 2, respectively (i.e. being one of the fragments or sequence variants disclosed herein) or each or both being identical to SEQ ID NO: 1 and 2, in combination with any one of the polypeptides disclosed as SEQ ID NOs: 1-19 in WO 2012/136653 or with any one of the fragments or variants of these polypeptides disclosed on pages 9-18 in WO 2012/136653.

Also, the present invention also relates to immunogenic compositions that include a (poly)peptide of the present invention derived from SEQ ID NO: 1 (i.e. being one of the fragments or sequence variants disclosed herein) or being identical to SEQ ID NO: 1 in combination with any one of the polypeptides disclosed as SEQ ID NOs: 1-16 and 49 in WO 2015/082536 or with any of the fragments and variants of these polypeptides disclosed on

pages 10-25 in WO 215/082536. Further, the present invention relates to immunogenic compositions that include a (poly)peptide of the present invention derived from SEQ ID NO: 2 (i.e. being one of the fragments or sequence variants disclosed herein) or being identical to SEQ ID NO: 2 in combination with any one of the polypeptides disclosed as SEQ ID NOs: 1-16 and 49 in WO 2015/082536 or with any one of the fragments or variants of these polypeptides disclosed on pages 10-25 in WO 2015/082536. Also, the present invention relates to immunogenic compositions that include two (poly)peptides of the present invention derived from SEQ ID NO: 1 and 2, respectively (i.e. being one of the fragments or sequence variants disclosed herein) or each or both being identical to SEQ ID NOs: 1 and 2, in combination with any one of the polypeptides disclosed as SEQ ID NOs: 1-16 and 49 in WO 2015/082536 or with any one of the fragments or variants of these polypeptides disclosed on pages 10-25 in WO 2015/082536.

The present invention also relates to immunogenic compositions that include a nucleic acid that encodes and is capable of effecting expression of a (poly)peptide of the present invention derived from SEQ ID NO: 1 (i.e. the (poly)peptide being one of the fragments or sequence variants disclosed herein) or being identical to SEQ ID NO: 1, in combination with a nucleic acid encoding and being capable of effecting expression of 1) any one of the polypeptides disclosed as SEQ ID NOs: 1-19 in WO 2012/136653 or 2) any one of the fragments and variants of these polypeptides disclosed on pages 9-18 in WO 2012/136653. Further, the present invention relates to immunogenic compositions that include nucleic acid that encodes a (poly)peptide of the present invention derived from SEQ ID NO: 2 (i.e. the (poly)peptide being one of the fragments or sequence variants disclosed herein) or being identical to SEQ ID NO: 2, in combination with a nucleic acid encoding and being capable of effecting expression of 1) any one of the polypeptides disclosed as SEQ ID NOs: 1-19 in WO 2012/136653 or 2) any one of the fragments or variants of these polypeptides disclosed on pages 9-18 in WO 2012/136653. The present invention also relates to immunogenic compositions that include one or more nucleic acids that encodes and is capable of effecting expression of (poly)peptides of the present invention derived from (or identical with) SEQ ID NOs: 1 and 2 (i.e. full-length proteins, fragments or sequence variants disclosed herein) in combination with a nucleic acid encoding and being capable of effecting expression of 1) any one of the polypeptides disclosed as SEQ ID NOs: 1-19 in WO 2012/136653 or 2) any one of the fragments and variants of these polypeptides disclosed on pages 9-18 in WO 2012/136653. Such a nucleic acid is typically an expression vector, either DNA-based or RNA-based. It is also within the ambit of the present invention that the 2 nucleic acids may be fused and part of one single nucleic acid that is capable of expressing two different immunogens or one single immunogen which constitutes a fusion protein. Thus the "combination of nucleic acids" can be in the form of separate nucleic acids that each encode a

(poly)peptide or it can be in the form of a single nucleic acid that includes coding sequences from both of the (poly)peptides.

The present invention also relates to immunogenic compositions that include a nucleic acid that encodes and is capable of effecting expression of a (poly)peptide of the present invention derived from SEQ ID NO: 1 (i.e. the (poly)peptide being one of the fragments or sequence variants disclosed herein) or being identical to SEQ ID NO: 1, in combination with a nucleic acid encoding and being capable of effecting expression of 1) any one of the polypeptides disclosed as SEQ ID NOs: 1-16 and 49 in WO 2015/082536 or 2) any one of the fragments and variants of these polypeptides disclosed on pages 10-25 in WO 215/082536.

Further, the present invention relates to immunogenic compositions that include nucleic acid that encodes a (poly)peptide of the present invention derived from SEQ ID NO: 2 (i.e. the (poly)peptide being one of the fragments or sequence variants disclosed herein) or being identical to SEQ ID NO: 2, in combination with a nucleic acid encoding and being capable of effecting expression of 1) any one of the polypeptides disclosed as SEQ ID NOs: 1-16 and 49 in WO 2015/082536 or 2) any one of the fragments or variants of these polypeptides disclosed on pages 10-25 in WO 2015/082536. Such a nucleic acid is typically an expression vector, either DNA-based or RNA-based. It is also within the ambit of the present invention that the 2 nucleic acids may be fused and part of one single nucleic acid that is capable of expressing two different immunogens or one single immunogen which constitutes a fusion protein. Thus the "combination of nucleic acids" can be in the form of separate nucleic acids that each encode a (poly)peptide or it can be in the form of a single nucleic acid that includes coding sequences from both of the (poly)peptides.

WO 2012/136653 and WO 2015/082536 are for these reasons incorporated in their entirety by reference herein.

Treatment methods of the invention

The method of the sixth aspect of the invention generally relates to induction of immunity and as such also entails method that relate to treatment, prophylaxis and amelioration of disease.

When immunization methods entail that a polypeptide of the invention or a composition comprising such a polypeptide is administered the animal (e.g. the human) typically receives between 0.5 and 5,000 µg of the polypeptide of the invention per administration.

In preferred embodiments of the sixth aspect, the immunisation scheme includes that the animal (e.g. the human) receives a priming administration and one or more booster administrations.

Preferred embodiments of the 6th aspect of the invention comprise that the administration is for the purpose of inducing protective immunity against *S. aureus*. In this embodiment it is particularly preferred that the protective immunity is effective in reducing the risk of attracting infection with *S. aureus* or is effective in treating or ameliorating infection with *S. aureus*.

As mentioned herein, the preferred vaccines of the invention induce humoral immunity, so it is preferred that the administration is for the purpose of inducing antibodies specific for *S. aureus* and wherein said antibodies or B-lymphocytes producing said antibodies are subsequently recovered from the animal.

But, as also mentioned the method of the 6th aspect may also be useful in antibody production, so in other embodiments the administration is for the purpose of inducing antibodies specific for *S. aureus* and wherein B-lymphocytes producing said antibodies are subsequently recovered from the animal and used for preparation of monoclonal antibodies.

Pharmaceutical compositions can as mentioned above comprise polypeptides, antibodies, or nucleic acids of the invention, optionally in admixture with polypeptides, antibodies or nucleic acids that are disclosed in WO 2012/136635 and/or WO 2015/082536. The pharmaceutical compositions will comprise a therapeutically effective amount thereof.

The term "therapeutically effective amount" or "prophylactically effective amount" as used herein refers to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction in physical symptoms, such as decreased body temperature. The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. Reference is however made to the ranges for dosages of immunologically effective amounts of polypeptides, cf. above.

However, the effective amount for a given situation can be determined by routine experimentation and is within the judgement of the clinician.

For purposes of the present invention, an effective dose will be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.

A pharmaceutical composition can also contain a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents. The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.

Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N. J. 1991).

Pharmaceutically acceptable carriers in therapeutic compositions may contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. Typically, the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier.

As is apparent from the claims, the invention also relates to related embodiments to the treatment and prophylaxis disclosed herein: the invention also includes embodiments where

- the polypeptide of the invention is for use as a pharmaceutical, in particular for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with *S. aureus*;

- the nucleic acid fragment of the invention or the vector of the invention is for use as a pharmaceutical, in particular for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with *S. aureus*;

- the transformed cell of the invention is for use as a pharmaceutical, in particular for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with *S. aureus*.

- the antibody, antibody fragment or antibody analogue of the invention is for use as a pharmaceutical, in particular for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with *S. aureus*.

EXAMPLE 1

Protective effect of SAR1262-25-519 in a murine model of peritonitis

The purpose of the experiment was to test the potentially protective effect of immunization with the SAR1262-25-519 (a protein consisting of the amino acid sequence SEQ ID NO: 2, residues 25-519) in an animal model of peritonitis.

Materials

NMRI mice, female (Taconic, Denmark)

Aluminum hydroxide (Alhydrogel 2.0%; Brenntag, cat. no. 21645-51-2)

Freund's incomplete adjuvant (Sigma, cat. no. F5506-10X10ML)

Staphylococcus aureus MRSA252, ST_36 batch #2

SAR1262-25-519 (recombinantly produced at University of Southern Denmark)

Preparation of vaccine

The protein was mixed with adjuvant as described below. Both aluminium hydroxide and Freund's incomplete adjuvant were used for the first immunization, whereas only aluminium hydroxide was used for the second and third rounds of immunization.

- The first immunization: Protein was mixed with aluminum hydroxide, in a ratio of 100 µl Alhydrogel per 125 µg protein, and incubated with end-over-end rotation for 1 hour. The suspension was centrifuged at 200 x g for 2 minutes and the supernatant removed, so that the remaining volume equaled 50% of the injection volume per mouse times the number of mice. Freund's incomplete adjuvant was added, in a ratio of 1:1 to the volume of protein and Alhydrogel, and the mixture was vortexed vigorously for 1 hour.

- Subsequent immunizations: The mice were boosted at regular intervals, using the same amount of protein mixed with Alhydrogel, as described above. Physiological saline was added to the suspension in order to reach the desired injection volume, when necessary.

Blood sampling

- 5 Blood samples were collected by tail vein puncture following a short exposure under a heat lamp. The blood is collected in eppendorf tubes containing 5 µl 0.5 M EDTA, and the sample mixed vigorously in order to mix the blood with the EDTA. The tubes are centrifuged at 1800 x g for 10 minutes, and the plasma fraction transferred to a second tube and stored at -80°C.

10 Immunization

- 8 female NMRI mice were immunized with recombinant SAR1262-25-519 – these mice were numbered 9-16 in the text below. 6 mice in a control group were immunized with adjuvant only. Each mouse was immunized subcutaneously (SC) or intraperitoneally (IP) three times at 2-4 week intervals. At all three immunizations in the test group 50 µg protein was injected
15 into each mouse. For the first immunization the proteins were mixed with aluminum hydroxide (Al(OH)₃) and Freund's incomplete adjuvant, whereas only Al(OH)₃ was used for the subsequent immunizations. Blood samples were collected from each animal approximately 10 days after the last immunization for analysis of antibody titer.

Preparation of bacterial inoculum

- 20 The bacteria used in the animal model of peritonitis were prepared in advance and frozen to -80°C in aliquots:

Bacterial matter is streaked out on a blood agar plate and incubated at 37°C over night.

- 25 A single colony of *S. aureus* is used for the inoculation of 30 ml of tryptic soy broth (TSB) media. The culture is incubated at 37°C, with continuous shaking, over night.

The following day, 1 litre of TSB media is inoculated with 10 ml of the overnight culture, and incubated at 37°C and continuous shaking for 6 hours. The bacterial suspension is centrifuged at 3000 x g for 10 minutes, and the pellet washed twice in 400 ml sterile phosphate buffered saline (PBS). After each wash the bacterial

suspension is centrifuged at 3000 x g for 10 minutes. The bacterial pellet is resuspended in 10-15 ml PBS, and glycerol is added to the final concentration is 16%. The suspension is thoroughly mixed, aliquoted into 1 ml aliquots and stored at -80°C.

5 In order to determine the number of CFU per ml in the freeze stock, aliquots are thawed on ice, and serially diluted in sterile saline. The dilutions are plated on TSB agar plates, and incubated at 37°C, over night. The number of CFU per ml is determined the following day. The procedure is carried out in duplicate, i.e. for two aliquots, to verify that the aliquots are homogenous.

10 Immediately prior to inoculation, the aliquots were thawed and diluted in sterile saline to the desired inoculum size, i.e. number of colony forming units (CFU) per inoculum volume.

Challenge setup

The mice were housed at the Biomedical Laboratory at the University of Southern Denmark. The animals were kept in an environment characterized by a 12 hours light-dark cycle and temperature and humidity control. They had access to food and water ad libitum. The experimental procedures were carried out in accordance with the guidelines of the Danish National Animal Ethics Committee.

20 The experiments were performed in class 2 certified facilities at the Biomedical Laboratory. Each mouse was inoculated intraperitoneally with 7.0×10^9 CFU of *Staphylococcus aureus* MRSA252. Following inoculation the mice were assessed daily to register symptoms and development of disease over the course of the 7 day challenge. To ensure a consistent evaluation of all animals, each animal was scored individually following the scale for clinical symptoms given in the following table.

	Score
Normal behavior	0 = no; 1 = yes
Normal appearance	0 = no; 1 = yes
Eye condition	0 = normal; 1 = mild irritation; 2 = one closed; 3 = both closed
Diarrhea	0 = no; 1 = yes
Changes in fur	0 = no; 1 = yes
Hunchback	0 = no; 1 = yes
Activity	0 = normal; 1 = low activity; 2 = no activity

The challenge was a lethal challenge without humane endpoints, hence those animals that could not combat the lethal *S. aureus* infection died of the infection. No animals were euthanized.

Results - survival

- 5 The survival of immunized mice was compared to the survival of mice in the control group, i.e. mice only receiving adjuvants. Fig. 1 shows the survival curve of the mice immunized with SAR1262-25-519. One mouse (#16) had to be euthanized prior to challenge, hence only 7 vaccinated mice were subjected to challenge infection.

Results - Clinical symptoms

- 10 The results of the clinical scoring are given in the following table. The raw data of the survival within each group is also given here (see the last lines beneath the daily registration of clinical symptoms).

	Scores for Mouse #						
	9	10	11	12	13	14	15
Day 1 post infection							
Normal behavior	0	0	0	0	0	0	0
Normal appearance	0	0	0	0	0	0	0
Eye condition	2	1	3	2	3	1	1
Diarrhea	1	1	0	0	0	1	0
Changes in fur	1	1	1	1	1	1	1
Hunch back	1	1	1	1	1	1	1
Activity	1	1	1	1	1	1	0
Dead (morning)	0	0	0	0	0	0	0
Day 2 post infection							
Normal behavior	0	1	0	0	0	-	1
Normal appearance	0	1	0	0	0	-	1
Eye condition	0	0	1	0	0	-	0
Diarrhea	0	0	0	1	0	-	0
Changes in fur	1	0	1	1	1	-	0
Hunch back	1	0	1	1	1	-	0
Activity]	0	0	1	1	1	-	0
Dead (morning)	0	0	0	0	0	1	0

	Scores for Mouse #						
	9	10	11	12	13	14	15
Day 3 post infection							
Normal behavior	1	1	0	0	0	-	1
Normal appearance	1	1	0	0	0	-	1
Eye condition	0	0	0	1	0	-	0
Diarrhea	0	0	0	1	0	-	0
Changes in fur	0	0	1	1	1	-	0
Hunch back	0	0	1	1	1	-	0
Activity	0	0	0	1	0	-	0
Dead (morning)	0	0	0	0	0	1	0
Day 4 post infection							
Normal behavior	0	1	1	0	0	-	1
Normal appearance	0	1	1	0	0	-	1
Eye condition	0	0	0	0	0	-	0
Diarrhea	0	0	0	0	0	-	0
Changes in fur	1	0	0	1	1	-	0
Hunch back	1	0	0	1	1	-	0
Activity	0	0	0	0	0	-	0
Dead (morning)	0	0	0	0	0	1	0
Day 5 post infection							
Normal behavior	0	1	1	0	0	-	1
Normal appearance	0	1	1	0	0	-	1
Eye condition	0	0	0	0	0	-	0
Diarrhea	0	0	0	0	0	-	0
Changes in fur	1	0	0	1	1	-	0
Hunch back	1	0	0	1	1	-	0
Activity	0	0	0	0	0	-	0
Dead (morning)	0	0	0	0	0	1	0
Day 6 post infection							
Normal behavior	1	1	1	0	0	-	1
Normal appearance	1	1	1	0	0	-	1
Eye condition	0	0	0	0	0	-	0
Diarrhea	0	0	0	0	0	-	0
Changes in fur	0	0	0	1	1	-	0
Hunch back	0	0	0	1	1	-	0
Activity	0	0	0	0	0	-	0

	Scores for Mouse #						
	9	10	11	12	13	14	15
Dead (morning)	0	0	0	0	0	1	0
Day 7 past infection							
Normal behavior	1	1	0	0	0	-	1
Normal appearance	1	1	0	0	0	-	1
Eye condition	0	0	0	0	0	-	0
Diarrhea	0	0	0	0	0	-	0
Changes in fur	0	0	1	1	1	-	0
Hunch back	0	0	1	1	1	-	0
Activity	0	0	0	0	0	-	0
Dead (morning)	0	0	0	0	0	1	0
CFU, right kidney							
dilution 10 ² CFU/ml	0	4	3	>300	>300	-	0
dilution 10 ³ CFU/ml	0	0	0	>300	43	-	0
dilution 10 ⁴ CFU/ml	0	0	0	260	3	-	0

Results - Antibody Titre

Prior to challenge onset blood was drawn from the mice. The plasma was used for subsequent analysis of antibody titer, using ELISA. Antibody titres are shown in Fig. 2.

Conclusion

- The lethal challenge with *MRSA252* showed that prior immunization with SAR1262-25-519 had a protective effect, resulting in survival of a significant number of immunized animals.. Immunization elicited an antibody response, though some animals immunized with SAR1262-25-519 had a lower antibody titer to the antigen compared to the other animals in that group.

EXAMPLE 2

Protective effect of SAR2635-1-199 in a murine model of peritonitis

The purpose of the experiment was to test the potentially protective effect of immunization with SAR2635-1-199 (the protein with the amino acid sequence SEQ ID NO: 1) in an animal model of peritonitis.

Materials

NMRI mice, female (Taconic, Denmark)

GERBU Adjuvant LQ (Biotechnik GmbH, #3000)

Staphylococcus aureus MRSA252, ST_36 batch #1

10 SAR2635-1-199 (recombinantly produced at the University of Southern Denmark)

Immunization

8 female NMRI mice were immunized with recombinant SAR 2635-1-199 in combination with adjuvant. 8 mice in the control group received adjuvant only. Each mouse was immunized subcutaneously three times at 2-3 weeks intervals (50, 36, and 16 days prior to initiation of challenge infection). At all three immunizations 50 µg protein formulated with GERBU adjuvant was injected into each mouse.

The protein was mixed with GERBU adjuvant in a ratio of 100 µl GERBU to 50 µg protein. If necessary, sterile saline was added to the suspension in order to reach the desired injection volume per animal. Before injection the solution was gently mixed using a pipette

20 Preparation of bacterial inoculum and challenge setup

These procedures were carried out exactly as described in Example 1.

Results - Survival

The survival of protein-immunized mice was compared to the survival of mice in the control group, i.e. mice only immunized with adjuvant. Fig. 3 shows the survival curve of the mice immunized with SAR2635-1-199. As is apparent, the vaccinated mice exhibited a significantly increased survival.

Conclusion

The lethal challenge with MRSA252 showed that prior immunization with SAR2635-1-199 had a protective effect, resulting in survival of a significant number of immunized animals.

EXAMPLE 3

5 *The protective effect fo SAR2635-1-199 and SAR1262-25-519 in a murine model of peritonitis*

The purpose of the experiment was to test the potentially protective effect of immunization with the SAR2635-1-199 and SAR1262-25-519 in an animal model of peritonitis.

10 Immunization with both antigens was proven to elicit protection against an otherwise lethal infection with *Staphylococcus aureus* MRSA252. The supplier of experimental animals was different than in Examples 1 and 2, so the normal inoculation dose of 6.5×10^9 CFU of *Staphylococcus aureus* MRSA252 was not lethal to 90% (LD90) of the animals. This influences the results presented here, as proteins that appear non-protective in an LD45 challenge might generate protection in a "traditional" LD90 challenge.

15 Materials

NMRI mice, female (Janvier, France)

Aluminum hydroxide (Alhydrogel 2.0%; Brenntag, cat. no. 21645-51-2)

Freund's incomplete adjuvant (Sigma, cat. no. F5506-10X10ML)

Staphylococcus aureus MRSA252, ST_36, batch #2

20 SAR2635-1-199 (recombinantly produced at the University of Southern Denmark)

SAR1262-25-519 (recombinantly produced at the University of Southern Denmark)

Immunizations

Vaccines were prepared as described in Example 1.

25 2 groups of 20 female NMRI mice were immunized with recombinant protein in combination with adjuvant. The groups were immunized with either SAR2635-1-199 (polypeptide consisting of the amino acid sequence SEQ ID NO: 1) and SAR1262-25-519 (polypeptide consisting of residues 25-519 of SEQ ID NO: 2), respectively. 20 mice in a control group received adjuvant only. Each mouse was immunized subcutaneously three times at

approximately two week intervals (42, 28 and 14 days prior to initiation of challenge infection). At all three immunizations 25 µg protein was injected into each mouse. For the first immunization the proteins were mixed with aluminum hydroxide (Al(OH)₃) and Freund's incomplete adjuvant, whereas only Al(OH)₃ was used for the subsequent immunizations.

5 Temperature transponders

Four days before inoculation, temperature transponders (BMDS, cat. no. IPTT-300) were inserted into each mouse. The mice were briefly anaesthetised by inhalation of isoflurane, and a temperature transponder inserted underneath the skin on the lower back or side of the mouse.

- 10 Using a compatible wireless scanner (BMDS Smart Probe; BMDS, cat. no. DAS-7007s) body temperature could be registered when placing the scanner close to the transponders underneath the skin of the mouse.

Preparation of bacterial inoculum and challenge setup

These procedures were carried out exactly as described in Example 1.

15 Results - survival

The survival of immunized mice was compared to the survival of mice in the control group, i.e. mice immunized with adjuvants only. Figures 4 and 5 survival curves of the mice immunized with SAR2635-1-199 and SAR1262-25-519, respectively.

Results – clinical symptoms

- 20 The results of the clinical scoring are given in the following tables. The raw data of the survival within each group is also given here (see the last lines beneath the daily registration of clinical symptoms). The first 3 tables show clinical data for SAR2635-1-199, whereas the last 3 tables show data for SAR1262-25-599.

Mouse #	R1	R2	R3	R4	S1	S2	S3	R1	R2	R3	R4	S1	S2	R1	R2	R3	R4	S1	S2	S3
Day 0 post infection																				
Temperature (°C)	36.2	37.0	36.8	36.8	37.3	36.9	37.1	37.0	36.6	37.6	37.3	38.4	38.1	38.0	38.1	38.7	38.4	38.6	38.0	39.3
Weight (g)	35.7	33.5	37.0	39.5	40.5	37.2	36.5	36.8	33.9	39.8	37.9	44.8	38.0	40.5	37.5	33.0	37.0	37.3	37.7	32.0
Day 1 post infection																				
Temperature (°C)	38.5	37.9	37.9	37.8	38.5	37.7	37.5	37.6	37.5	37.3	36.7	37.2	37.3	37.9	38	37.4	37.6	37.4	36.3	36.3
Weight (g)	32.6	31.5	34	37.6	38.6	35.3	35	34.2	32.9	37	36.3	42.8	35.3	40	30	35	37.5	37.3	30.8	30.8
Weight loss (%)	9	6	8	5	5	5	4	7	3	7	4	4	7	1	100	9	5	-1	1	4
Eye condition	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	1
Diarrhea	0	0	0	0	1	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0
Changes in fur	1	1	1	0	1	1	1	0	0	0	1	1	1	0	0	0	0	0	0	1
Hunch back	1	1	1	0	1	1	1	0	0	0	1	1	1	0	0	0	0	0	0	1
Activity	1	0	0	0	1	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0
Dead (morning)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Temperature (evening, °C)	37.9	38	37.3	37.5	38.5	37.5	37.4	37.9	37.8	37.1	36.5	37.4	37.5	38.5	38.5	37.2	37.8	37.2	38	38
Dead (evening)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Day 2 post infection																				
Temperature (°C)	36.8	37.8	37.1	37.9	36.6	37.2	37.9	37	37.6	37	36	37.5	37.9	37.9	37.8	37.1	37.7	37.2	37.6	37.6
Weight (g)	32.3	32.5	34.5	38.4	36.5	34.2	34.3	34.4	33.1	36.7	34.6	40.4	33	40	28.8	35	37	37	29.4	29.4
Weight loss (%)	10	3	7	3	10	8	6	7	2	8	9	10	13	1	100	13	5	1	2	8
Eye condition	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Diarrhea	0	0	0	0	1	0	0	0	0	0	0	1	0	0	1	0	0	0	0	1
Changes in fur	0	0	0	0	1	0	0	0	0	0	1	1	1	0	1	0	0	0	0	1
Hunch back	0	0	0	0	1	0	0	0	0	0	1	1	1	0	1	0	0	0	0	1
Activity	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1
Dead (morning)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0

[illegible]

[illegible]

Conclusion

The lethal challenge with MRSA252 showed that prior immunization with SAR2635-1-199 and SAR1262-25-519 had a protective effect, resulting in survival of a significant number of the immunized animals, even in an animal model, where the challenge dose of 6.5×10^9 CFU of *Staphylococcus aureus* MRSA252 only corresponds to LD45 (and not LD90).

SEQUENCE INFORMATION

The sequence listing included sets forth the sequences of polypeptides and nucleic acids of the present invention. For easy reference, the sequences are presented in the following:

SEQ ID NO: 1

10 MTEKEKMLAEKWYDANFDQDLINERARAKDICFELNHTKPSDKNKRKELIDELFQTTTNDVSIIPFDTDY
GWNVVLGKNVYVNTNCYFMDGGQITIGDNVFIGPNCGYTATHPLNFHHRNEGFEKAGPINIGSNTWFG
GHVAVLPGVITIGESVIGAGSVVTKDIPPHSLAVGNPCKVVRKIDNEVPSEALNDET LN

SEQ IN NO: 2 (2',3'-cyclic-nucleotide 2'-phosphodiesterase / Conserved virulence factor A);
underlined part used for recombinant expression (residues 25-519)

15 MNLLSLLLILLGII LGVVG YVVARNLLLQKQS QARQTAEDIVNQAHKEADNIKKEKLLEAKEENQILREQT
EALRERRSELQRQETRLLQKEENLERKSDLLDKKDEILEQKESKIEEKQQQVDAKESSVQTLIMKHEQEL
ERISGLTQEEAINEQLQRVEEELSQDIAVLVKEKEKEAKEKVDKTAKELLATAVQRLAADHTSESTVS VVN
LPNDEMKGRIIGREGRNIRTLETLTGIDLIIDDTPEAVILSGFDPIRREIARTALVNLVSDGRIHPGRIEDMV
EKARKEVDDIIREAGEQATFEVNAHNMHDPDLVKIVGRLNYRTSYGQNVLKHSIEVAHLASMLAAELGEDE
20 TLAKRAGLLHDVGKAIDHEVEGSHVEIGVELAKKYGENETVINAIHSHHGDVEPTSIISILVAAADALSAAR
PGARKETLENYIRRLERLETLSesydgvekaFAIQAGREIRVIVSPEEIDDLKSYRLARDIKNQIEDELQYPG
HIKVTVVRETRAVEYAK

SEQ ID NO: 3 (DNA encoding SEQ ID NO: 1)

ATGACTGAAAAAGAAAAATGTTAGCAGAAAAATGGTACGATGCAAACCTTGATCAAGACTTAATCAAT
25 GAACGTGCACGAGCGAAAGATATTTGCTTTGAATTAATCATACAAAGCCGAGTGACAAAAATAAAAG
AAAGGAATTAATCGATGAATTATTTCAAACAACAACAGACAATGTAAGTATTTGATTCTTTTGATACA
GATTATGGTTGGAACGTAACTAGGAAAAAATGTCTATGTAAACACCAATTGTTATTTTATGGATGGT
GGACAGATTACAATTGGCGATAATGTTTTATAGGACCTAATTGTGGATTCTACACAGCAACACATCCA
CTTAATTTTCATCATAGAAATGAAGGATTTGAAAAAGCAGGACCAATTAATATTGGCAGTAATACTTGG
30 TTTGGCGGACATGTAGCCGTGCTTCCGGGAGTGACGATTGGAGAAGGCAGTGTGATTGGTGCTGGTA
GTGTTGTCACCAAAGATATTCCGCCACACAGTTTAGCGGTTGGAAACCCTTGTAAGTCGTTCGTAAA
ATTGATAATGAGGTACCATCAGAAGCATTGAACGATGAAACACTAAATTAG

SEQ IN NO: 4 (DNA encoding SEQ ID NO: 2, underlined part encoding residues 25-519 of SEQ ID NO:)

ATGAATTTATTAAGCCTCCTACTCATTTTTGCTGGGGATCATTCTAGGAGTTGTTGGAGGGTATGTTGTT
GCCCCGAAATTTGTTGCTTCAAAAGCAATCACAAGCTAGACAAACTGCCGAAGATATTGTAAATCAAGC
5 ACATAAAGAAGCTGACAATATCAAAAAGAGAAATTACTTGAGGCAAAAGAAGAAAACCAAATCCTAA
GAGAACAACTGAAGCAGAACTACGAGAAAGACGTAGCGAACTTCAAAGACAAGAAACCCGACTTCTT
CAAAAAGAAGAAAACCTTAGAGCGTAAATCTGATCTATTAGATAAAAAAGATGAGATTTTAGAGCAAAAA
GAATCAAAAATTGAAGAAAAACAACAAGTAGATGCAAAAGAGAGTAGTGTTCAAACGTTAATAAT
GAAGCATGAACAAGAATTAGAACGCATCTCCGGTCTCACTCAAGAAGAAGCTATTAATGAGCAACTTC
10 AAAGAGTAGAGGAAGAACTGTCACAAGATATTGCAGTACTTGTTAAAGAAAAAGAAAAAGAAGCTAAA
GAAAAAGTTGATAAAACAGCAAAAGAATTATTAGCTACAGCAGTACAAAGATTAGCAGCAGATCACAC
AAGTGAATCAACGGTATCAGTAGTTAACTTACCTAATGATGAGATGAAAGGTCGAATCATTGGACGTG
AAGGACGAAACATCCGTACACTTGAACTTTAACTGGCATTGATTTAATTATTGATGACACACCAGAAG
CAGTTATATTATCTGGTTTTGATCCAATAAGAAGAGAAATTGCTAGAACAGCACTTGTTAACTTAGTAT
15 CTGATGGACGTATTCATCCAGGTAGAATTGAAGATATGGTCGAAAAAGCTAGAAAAGAAGTAGACGAT
ATTATAAGAGAAGCAGGTGAACAAGCTACATTTGAAGTGAACGCACATAATATGCATCCTGACTTAGT
AAAAATTGTAGGGCGTTTAACTATCGTACAAGTTACGGTCAAAATGTACTTAAACATTCAATTGAAGT
TGCGCATCTTGCTAGTATGTTAGCTGCTGAGCTAGGCGAAGATGAGACATTAGCGAAACGAGCTGGA
CTTTTACATGATGTTGGTAAAGCAATTGATCATGAAGTAGAAGGTAGTCATGTTGAAATCGGTGTAGAA
20 TTAGCGAAAAAATATGGTGAAAATGAAACAGTTATTAATGCAATCCATTCTACCATGGTGATGTTGAA
CCTACATCTATTATATCTATCCTTGTTGCTGCTGCAGATGCATTGTCTGCGGCTCGTCCAGGTGCAAGA
AAAGAAACATTAGAGAATTATATTCGTGATTAGAACGTTTAGAAACGTTATCAGAAAGTTATGATGGT
GTAGAAAAAGCATTTGCGATTGAGGAGGTAGAGAAATCCGAGTGATTGTATCTCCTGAAGAAATTGA
TGATTTAAATCTTATCGATTGGCTAGAGATATTAATAATCAGATTGAAGATGAATTACAATATCCTGGT
25 CATATCAAGGTGACAGTTGTTGAGAGACTAGAGCAGTAGAATATGCGAAATAA

SEQ ID NO: 5 (RNA encoding SEQ ID NO: 1)

AUGACUGAAAAAGAAAAAUGUUAGCAGAAAAAUGGUACGAUGCAAACUUUGAUCAAGACUUAUUC
AAUGAACGUGCAGCAGCGAAAGAUUUUUGCUUUGAAUUAAAUCAUACAAAGCCGAGUGACAAAAAU
AAAAGAAAGGAAUUAAUUGAUGAAUUUUUCAAACAACAACAGACAAUGUAAGUAUUUUGAUUCCU
30 UUUUGAUACAGAUUAUGGUUGGAACGUUAAACUAGGAAAAAUGUCUAUGUAAACACCAAUUGUUUAU
UUUAUGGAUGGUGGACAGAUUACA AUUGGCGAUAAUGUUUUUAUAGGACCUAAUUGUGGAUUCUA
CACAGCAACACAUCACUUAUUUUUCAUCAUAGAAUUGAAGGAUUUGAAAAAGCAGGACCAAUUAA
UAUUGGCAGUAAUACUUGGUUUGGCGGACAUGUAGCCGUGCUUCCGGGAGUGACGAUUGGAGAA
GGCAGUGUGAUUGGUGCUUGGUAGUGUUGUCACCAAAGAUUUUCCGCCACACAGUUUAGCGGUUG
35 GAAACCCUUGUAAAGUCGUUCGUAAAAUUGAUAAUGAGGUACCAUCAGAAGCAUUGAACGAUGAAA
CACUAAAUUAG

SEQ ID NO: 6 (RNA encoding SEQ ID NO: 2, underlined part encoding residues 25-519 of SEQ ID NO: 2)

AUGAAUUUUAAUAAAGCCUCCUACUUAUUUGCGUGGGGAUCAUUCUAGGGAUUUGUUGGAGGGUAUAGU
 UGUUUGCCCGAAAUUUGUUGCUUCAAAGCAUACAAGCUAGACAAACUGCCGAAGAUUUUGUAAA
 5 UCAAGCACAUAAAGAAGCUGACAAUAUCAAAAAAGAGAAAUUACUUGAGGGCAAAAGAAGAAAACCA
AUCCUAAGAGAACAACUGAAGCAGAACUACGAGAAAGACGUAGCGAACUUCAAAGACAAGAAACC
CGACUUCUUCAAAAAGAAGAAAACUUGAGCGUAAAUCUGAUCUAUUAGAUAAAAAAGAUGAGAUU
UUAGAGCAAAAAGAAUCAAAAAUUGAAGAAAAACAACAACAGUAGAUGCAAAAGAGAGUAGUGUU
CAAACGUUAAUAAUGAAGCAUGAACAAGAAUUAAGAACGCAUCUCCGGUCUCACUCAAGAAGAAGCU
 10 AUUAAUGAGCAACUUCAAAGAGUAGAGGAAGAACUGUCACAAGAUUUUGCAGUACUUGUUAAAGAA
AAAGAAAAAGAAGCUAAAGAAAAAGUUGAUAAAACAGCAAAAGAAUUAUUAGCUACAGCAGUACAAA
GAUUAGCAGCAGAUACACAAGUGAAUCAACGGUAUCAGUAGUUAACUUAACCUAAUGAUGAGAUGA
AAGGUCGAAUCAUUGGACGUGAAGGACGAAACAUCCGUACACUUGAAACUUAACUGGCAUUGAU
UUAUUUAUUUGAUGACACACCAGAAGCAGUUUAUUAUUCUGGUUUUGAUCCAUAAGAAGAGAAAUU
 15 GCUAGAACAGCACUUGUUAACUUAAGUAUCUGAUGGACGUUUCAUCCAGGUAGAAUUGAAGAUU
GGUCGAAAAAGCUAGAAAAGAAGUAGACGAUUAUUAAGAGAAGCAGGUGAACAAGCUACAUUUGA
AGUGAACGCACAUAAUUGCAUCCUGACUUAAGUAAAAAUUGUAGGGCGUUUAAACUAUCGUACAAG
UUACGGUCAAAUUGUACUUAACAUAUCAAUUGAAGUUGCGCAUCUUGCUAGUAUGUUAGCUGCUG
AGCUAGGCGAAGAUGAGACAUUAGCGAAACGAGCUGGACUUUUACAUGAUGUUGGUAAAGCAAUU
 20 GAUCAUGAAGUAGAAGGUAGUCAUGUUGAAAUUCGGUGUAGAAUUAAGCGAAAAAAUUAUGGUGAAAA
UGAAACAGUUUAUUAAUGCAAUCCAUUCUCACCAUGGUGAUGUUGAACCUCACUUAUUUAUCUUAU
CCUUGUUGCUGCUGCAGAUGCAUUGUCUGCGGCUCGUCCAGGUGCAAGAAAAGAAACAUUAGAGA
AUUUAUAUUCGUCGAUUAGAACGUUUAGAAACGUUAUCAGAAAGUUAUGAUGGUGUAGAAAAAGCA
UUUGCGAUUCAGGCAGGUAGAGAAAUCCGAGUGAUUGUAUCUCCUGAAGAAAUUGAUGAUUUAAA
 25 AUCUUAUCGAUUGGCUAGAGAUUUAAAAUUCAGAUUGAAGAUAGAAUJACAUAUCCUGGUCAUUA
CAAGGUGACAGUUGUUCGAGAGACUAGAGCAGUAGAAUUAUGCGAAAUA

CLAIMS

1. A polypeptide comprising

a) an amino acid sequence selected from SEQ ID NO: 1 and SEQ ID NO: 2, or

b) an amino acid sequence consisting of at least or exactly 5 contiguous amino acid residues
5 from the amino acid sequence of a), or

c) an amino acid sequence having a sequence identity of at least 60% with the amino acid
sequence of a),

d) an amino acid sequence having a sequence identity of at least 60% with the amino acid
sequence of b), or

10 e) an assembly of amino acids derived from SEQ ID NO: 1 or 2, which has essentially the
same 3D conformation as in the protein from which said assembly is derived so as to
constitute a B-cell epitope,

said polypeptide being antigenic in a mammal.

2. The polypeptide according to claim 1, wherein the at least or exactly 5 contiguous
15 amino acids are

1) at least or exactly or at most 6, such as at least or exactly or at most 7, at least or exactly
or at most 8, at least or exactly or at most 9, at least or exactly or at most 10, at least or
exactly or at most 11, at least or exactly or at most 12, at least or exactly or at most 13, at
20 least or exactly or at most 14, at least or exactly or at most 15, at least or exactly or at most
16, at least or exactly or at most 17, at least or exactly or at most 18, at least or exactly or
at most 19, at least or exactly or at most 20, at least or exactly or at most 21, at least or
exactly or at most 22, at least or exactly or at most 23, at least or exactly or at most 24, at
least or exactly or at most 25, at least or exactly or at most 26, at least or exactly or at most
25 27 at least or exactly or at most 28, at least or exactly or at most 29, at least or exactly or at
most 30, at least or exactly or at most 31, at least or exactly or at most 32, at least or
exactly or at most 33, at least or exactly or at most 34, and at least or exactly or at most 35,
at least or exactly or at most 36, at least or exactly or at most 37, at least or exactly or at
most 38, at least or exactly or at most 39, at least or exactly or at most 40, at least or
30 exactly or at most 41, at least or exactly or at most 42, at least or exactly or at most 43, at
least or exactly or at most 44, at least or exactly or at most 45, at least or exactly or at most
46, at least or exactly or at most 47, at least or exactly or at most 48, at least or exactly or
at most 49, at least or exactly or at most 50, at least or exactly or at most 51, at least or
exactly or at most 52, at least or exactly or at most 53, at least or exactly or at most 54, at
35 least or exactly or at most 55, at least or exactly or at most 56, at least or exactly or at most
57, at least or exactly or at most 58, at least or exactly or at most 59, at least or exactly or
at most 60, at least or exactly or at most 61, at least or exactly or at most 62, at least or

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

exactly or at most 489, at least or exactly or at most 490, at least or exactly or at most 491, at least or exactly or at most 492, at least or exactly or at most 493, at least or exactly or at most 494, at least or exactly or at most 495, at least or exactly or at most 496, at least or exactly or at most 497, at least or exactly or at most 498, at least or exactly or at most 499, at least or exactly or at most 500, at least or exactly or at most 501, at least or exactly or at most 502, at least or exactly or at most 503, at least or exactly or at most 504, at least or exactly or at most 505, at least or exactly or at most 506, at least or exactly or at most 507, at least or exactly or at most 508, at least or exactly or at most 509, at least or exactly or at most 510, at least or exactly or at most 511, at least or exactly or at most 512, at least or exactly or at most 513, at least or exactly or at most 514, at least or exactly or at most 515, at least or exactly or at most 516, at least or exactly or at most 517, or at least or exactly or at most 518 contiguous amino acid residues of SEQ ID NO: 2.

3. The polypeptide according to claim 1 or 2, wherein the sequence identity with the amino acid sequence of a) is at least 65%, such as at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.

4. The polypeptide according to claim 1 or 2, wherein the sequence identity with the amino acid sequence of b) is at least 60%, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.

5. The polypeptide according to any one of the preceding claims, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, and 195 in SEQ ID NO: 1.

6. The polypeptide according to any one of claims 1-4, wherein the at least or exactly or at most 5 contiguous amino acid residues has an N-terminal amino acid residue corresponding to any one of amino acid residues 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,

15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,
39, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 63, 64,
65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88,
89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108,
5 109, 110, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125,
126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143,
144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 171,
172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189,
190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207,
10 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225,
226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243,
244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 271,
272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289,
290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307,
15 308, 309, 310, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324,
325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342,
343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360,
361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378,
379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396,
20 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414,
415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432,
433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450,
451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468,
469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486,
25 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504,
505, 506, 507, 508, 509, 510 and 511, 512, 513, 514, and 515 in SEQ ID NO: 2.

7. The polypeptide according to any one of the preceding claims, which is fused or conjugated to an immunogenic carrier molecule.

8. The polypeptide according to claim 7, wherein the immunogenic carrier molecule is a
30 polypeptide that induces T-helper lymphocyte responses in a majority of humans, such as
immunogenic carrier proteins selected from the group consisting of keyhole limpet
hemocyanin or a fragment thereof, tetanus toxoid or a fragment thereof, diphtheria toxoid
or a fragment thereof.

9. The polypeptide according to any one of the preceding claims, which is capable of
35 inducing an adaptive immune response against the polypeptide in a mammal, in particular in
a human being.

10. The polypeptide according to claim 9, which is capable of inducing, in the mammal, a protective adaptive immune response against infection with *S. aureus*.

11. The polypeptide according to claim 10, which induces a humoral and/or a cellular immune response.

12. An isolated nucleic acid fragment, which comprises

i) a nucleotide sequence encoding a polypeptide according to any one of the preceding claims, or

ii) a nucleotide sequence consisting of the amino acid encoding part of the reading frame starting with residue 1 in any one of SEQ ID NOs: 3-6.

iii) a nucleotide sequence consisting of at least or exactly or at most 10 consecutive nucleotides in the amino acid encoding part of the reading frame starting with residue 1 in any one of SEQ ID NOs: 3-6,

iv) a nucleotide sequence having a sequence identity of at least 60% with the nucleotide sequence in i) or ii),

v) a nucleotide sequence having a sequence identity of at least 60% with the nucleotide sequence in iii),

vi) a nucleotide sequence complementary to the nucleotide sequence in i)-v), or

vii) a nucleotide sequence which hybridizes under stringent conditions with the nucleotide sequence in i)-vi).

13. The nucleic acid fragment according to claim 12, which is a DNA or an RNA fragment.

14. The nucleic acid fragment according to claim 12 or 13, wherein the nucleotide

sequence consists of at least or exactly or at most 11, such as at least or exactly or at most

12, at least or exactly or at most 13, at least or exactly or at most 14, at least or exactly or

at most 15, at least or exactly or at most 16, at least or exactly or at most 17 at least or

exactly or at most 18, at least or exactly or at most 19, at least or exactly or at most 20, at

least or exactly or at most 21, at least or exactly or at most 22, at least or exactly or at most

23, at least or exactly or at most 24, at least or exactly or at most 25, at least or exactly or

at most 26, at least or exactly or at most 27, at least or exactly or at most 28, at least or

exactly or at most 29, at least or exactly or at most 30, at least or exactly or at most 31, at

least or exactly or at most 32, at least or exactly or at most 33, at least or exactly or at most

34, at least or exactly or at most 35, at least or exactly or at most 36, at least or exactly or

at most 37, at least or exactly or at most 38, at least or exactly or at most 39, at least or

exactly or at most 40, at least or exactly or at most 41, at least or exactly or at most 42, at

least or exactly or at most 43, at least or exactly or at most 44, at least or exactly or at most

45, at least or exactly or at most 46, at least or exactly or at most 47, at least or exactly or

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

or exactly or at most 590, at least or exactly or at most 591, at least or exactly or at most 592, at least or exactly or at most 593, at least or exactly or at most 594, at least or exactly or at most 595, at least or exactly or at most 596, at least or exactly or at most 597, at least or exactly or at most 598, at least or exactly or at most 599, at least or exactly or at most consecutive nucleotides in the part of SEQ ID NO: 3, 4, 5, or 6 that encodes amino acids.

15. The nucleic acid fragment according to any one of claims 12-14, wherein the nucleotide sequence consists of at least or exactly or at most 600, at least or exactly or at most 601, at least or exactly or at most 602, at least or exactly or at most 603, at least or exactly or at most 604, at least or exactly or at most 605, at least or exactly or at most 606, at least or exactly or at most 607, at least or exactly or at most 608, at least or exactly or at most 609, at least or exactly or at most 610, at least or exactly or at most 611, at least or exactly or at most 612, at least or exactly or at most 613, at least or exactly or at most 614, at least or exactly or at most 615, at least or exactly or at most 616, at least or exactly or at most 617, at least or exactly or at most 618, at least or exactly or at most 619, at least or exactly or at most 620, at least or exactly or at most 621, at least or exactly or at most 622, at least or exactly or at most 623, at least or exactly or at most 624, at least or exactly or at most 625, at least or exactly or at most 626, at least or exactly or at most 627, at least or exactly or at most 628, at least or exactly or at most 629, at least or exactly or at most 630, at least or exactly or at most 631, at least or exactly or at most 632, at least or exactly or at most 633, at least or exactly or at most 634, at least or exactly or at most 635, at least or exactly or at most 636, at least or exactly or at most 637, at least or exactly or at most 638, at least or exactly or at most 639, at least or exactly or at most 640, at least or exactly or at most 641, at least or exactly or at most 642, at least or exactly or at most 643, at least or exactly or at most 644, at least or exactly or at most 645, at least or exactly or at most 646, at least or exactly or at most 647, at least or exactly or at most 648, at least or exactly or at most 649, at least or exactly or at most 650, at least or exactly or at most 651, at least or exactly or at most 652, at least or exactly or at most 653, at least or exactly or at most 654, at least or exactly or at most 655, at least or exactly or at most 656, at least or exactly or at most 657, at least or exactly or at most 658, at least or exactly or at most 659, at least or exactly or at most 660, at least or exactly or at most 661, at least or exactly or at most 662, at least or exactly or at most 663, at least or exactly or at most 664, at least or exactly or at most 665, at least or exactly or at most 666, at least or exactly or at most 667, at least or exactly or at most 668, at least or exactly or at most 669, at least or exactly or at most 670, at least or exactly or at most 671, at least or exactly or at most 672, at least or exactly or at most 673, at least or exactly or at most 674, at least or exactly or at most 675, at least or exactly or at most 676, at least or exactly or at most 677, at least or exactly or at most 678, at least or exactly or at most 679, at least or exactly or at most 680, at least or exactly or at most 681, at least or exactly or at most 682, at least or exactly or at most 683, at least or

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

exactly or at most 1484, at least or exactly or at most 1485, at least or exactly or at most 1486, at least or exactly or at most 1487, at least or exactly or at most 1488, at least or exactly or at most 1489, at least or exactly or at most 1490, at least or exactly or at most 1491, at least or exactly or at most 1492, at least or exactly or at most 1493, at least or exactly or at most 1494, at least or exactly or at most 1495, at least or exactly or at most 1496, at least or exactly or at most 1497, at least or exactly or at most 1498, at least or exactly or at most 1499, at least or exactly or at most 1500, at least or exactly or at most 1501, at least or exactly or at most 1502, at least or exactly or at most 1503, at least or exactly or at most 1504, at least or exactly or at most 1505, at least or exactly or at most 1506, at least or exactly or at most 1507, at least or exactly or at most 1508, at least or exactly or at most 1509, at least or exactly or at most 1510, at least or exactly or at most 1511, at least or exactly or at most 1512, at least or exactly or at most 1513, at least or exactly or at most 1514, at least or exactly or at most 1515, at least or exactly or at most 1516, at least or exactly or at most 1517, at least or exactly or at most 1518, at least or exactly or at most 1519, at least or exactly or at most 1520, at least or exactly or at most 1521, at least or exactly or at most 1522, at least or exactly or at most 1523, at least or exactly or at most 1524, at least or exactly or at most 1525, at least or exactly or at most 1526, at least or exactly or at most 1527, at least or exactly or at most 1528, at least or exactly or at most 1529, at least or exactly or at most 1530, at least or exactly or at most 1531, at least or exactly or at most 1532, at least or exactly or at most 1533, at least or exactly or at most 1534, at least or exactly or at most 1535, at least or exactly or at most 1536, at least or exactly or at most 1537, at least or exactly or at most 1538, at least or exactly or at most 1539, at least or exactly or at most 1540, at least or exactly or at most 1541, at least or exactly or at most 1542, at least or exactly or at most 1543, at least or exactly or at most 1544, at least or exactly or at most 1545, at least or exactly or at most 1546, at least or exactly or at most 1547, at least or exactly or at most 1548, at least or exactly or at most 1549, at least or exactly or at most 1550, at least or exactly or at most 1551, at least or exactly or at most 1552, at least or exactly or at most 1553, at least or exactly or at most 1554, at least or exactly or at most 1555, at least or exactly or at most 1556, at least or exactly or at most 1557, at least or exactly or at most 1558, at least or exactly or at most 1559 consecutive nucleotides in the part of SEQ ID NO: 4 or 6 that encodes amino acids.

16. The nucleic acid fragment according to any one of claims 12-15, wherein the sequence identity with the nucleotide sequence in i) or ii) is at least 65%, such as at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.

17. The nucleic acid fragment according to any one of claims 12-15, wherein the sequence identity with the nucleotide sequence in iii) is at least 65%, such as at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99%.

5 18. A vector comprising the nucleic acid according to any one of claims 12-17, such as a cloning vector or an expression vector.

19. The vector according to claim 18, which comprises in operable linkage and in the 5'-3' direction, an expression control region comprising an enhancer/promoter for driving expression of the nucleic acid fragment defined in claim 12-i), optionally a signal peptide
10 coding sequence, a nucleotide sequence defined in claim 12-i), and optionally a terminator.

20. The vector according to claim 18 or 19, wherein the expression control region drives expression in prokaryotic cell such as a bacterium, e.g. in E coli.

21. The vector according to claim any one of claims 18-20, which is capable of autonomous replication.

15 22. The vector according to any one of claims 18-21, which is capable of being integrated into the genome of a host cell.

23. The vector according to any one of claims 18-22, which is incapable of being integrated into the genome of a mammalian host cell.

24. The vector according to any one of claims 18-23, which is selected from the group
20 consisting of a virus, such as a attenuated virus, a bacteriophage, a plasmid, a minichromosome, and a cosmid.

25. A cell which is transformed so as to carry the vector according to any one of claims 18-24.

26. The transformed cell according to claim 25, which is capable of replicating the nucleic
25 acid fragment defined in claim 12-i).

27. The transformed cell according to claim 25, which is capable of expressing the nucleic acid fragment defined in claim 12-i).

28. The transformed cell according to any one of claims 25-27, which is selected from a prokaryotic cell and a eukaryotic cell.

29. The transformed cell according to any one of claims 25-28, which is a bacterial cell selected from the group consisting of *Escherichia* (such as *E. coli.*), *Bacillus* (e.g. *Bacillus subtilis*), *Salmonella*, and *Mycobacterium*, preferably non-pathogenic, e.g. *M. bovis* BCG.

30. The transformed cell according to any one of claims 25-29, which is stably transformed by having the nucleic acid defined in claim 12-i) stably integrated into its genome.

31. The transformed cell according to any one of claims 25-30, which secretes or carries on its surface the polypeptide according to any one of claims 1-11.

32. The transformed cell according to claim 31, wherein the cell is a bacterium and secretion is into the periplasmic space.

33. A cell line derived from a transformed cell according to any one of claims 25-32.

34. A pharmaceutical composition comprising a polypeptide according to any one of claims 1-11, a nucleic acid fragment according to any one of claims 12-17, a vector according to any one of claims 18-24, or a cell according to any one of claims 25-32, and a pharmaceutically acceptable carrier, vehicle or diluent.

35. The pharmaceutical composition according to claim 34, which further comprises an immunological adjuvant.

36. The pharmaceutical composition according to claim 35, wherein the adjuvant is an aluminium based adjuvant.

37. A method for inducing immunity in an animal by administering at least once an immunogenically effective amount of a polypeptide according to any one of claims 1-11, a nucleic acid fragment according to any one of claims 12-17, a vector according to any one of claims 18-24, a cell according to any one of claims 25-32, or a pharmaceutical composition according to any one of claims 34-36 so as to induce adaptive immunity against *S. aureus* in the animal.

38. The method according to claim 37, wherein, when the polypeptide according to any one of claim 1-11 or a composition comprising said polypeptide is administered, the animal receives between 0.5 and 5,000 µg of the polypeptide according to any one of claims 1-11 per administration.

5 39. The method according to claim 37 or 38, wherein the animal receives a first priming administration comprising said polypeptide and one or more booster administrations comprising said polypeptide.

40. The method according to any one of claims 37-39, wherein the animal is a human being.

10 41. The method according to any one of claims 37-40, wherein the administration is for the purpose of inducing protective immunity against *S. aureus*.

42. The method according to claim 41, wherein the protective immunity is effective in reducing the risk of attracting infection with *S. aureus* or is effective in treating or ameliorating infection with *S. aureus*.

15 43. The method according to any one of claims 37-40, wherein the administration is for the purpose of inducing antibodies specific for *S. aureus* and wherein said antibodies or B-lymphocytes producing said antibodies are subsequently recovered from the animal.

44. The method according to any one of claims 37-39, wherein the administration is for the purpose of inducing antibodies specific for *S. aureus* and wherein B-lymphocytes
20 producing said antibodies are subsequently recovered from the animal and used for preparation of monoclonal antibodies.

45. A polyclonal antibody in which the antibodies specifically bind to at least one polypeptide according to any one of claims 1-11, and which is essentially free from antibodies binding specifically to other *S. aureus* polypeptides.

25 46. An isolated monoclonal antibody or antibody analogue which binds specifically to a polypeptide according to any one of claims 1-11.

47. The isolated monoclonal antibody or antibody analogue according to claim 46, which is a monoclonal antibody selected from a multi-domain antibody such as a murine antibody, a chimeric antibody such as a humanized antibody, a fully human antibody, and single-domain

antibody of a llama or a camel, or which is an antibody analogue selected from a fragment of an antibody such as an Fab or an F(ab')₂, and an scFV.

48. A pharmaceutical composition comprising an antibody according to any one of claims 45-47 and a pharmaceutically acceptable carrier, vehicle or diluent.

5 49. A method for prophylaxis, treatment or amelioration of infection with *S. aureus*, in particular infection with multi-resistant *S. aureus*, comprising administering a therapeutically effective amount of an antibody according to any one of claims 45-47 or a pharmaceutical composition according to claim 48 to an individual in need thereof.

10 50. A method for determining, quantitatively or qualitatively, the presence of *S. aureus*, in particular the presence of multi-resistant *S. aureus*, in a sample, the method comprising contacting the sample with an antibody according to any one of claims 45-47 and detecting the presence of antibody bound to material in the sample.

15 51. A method for determining, quantitatively or qualitatively, the presence of antibodies specific for *S. aureus*, in particular the presence of antibodies specific for multi-resistant *S. aureus*, in a sample, the method comprising contacting the sample with a polypeptide according to any one of claims 1-11 and detecting the presence of antibody binding said polypeptide.

20 52. A method for determining, quantitatively or qualitatively, the presence of a nucleic acid characteristic of *S. aureus*, in particular the presence of a nucleic acid characteristic of multi-resistant *S. aureus*, in a sample, the method comprising contacting the sample with a nucleic acid fragment according to any one of claims 12-17 and detecting the presence of nucleic acid in the sample that hybridized to said nucleic acid fragment.

25 53. The method according to claim 52, which includes at least one step of molecular amplification of the nucleic acid which is to be detected in the sample, for instance a step of PCR amplification.

54. A method for the preparation of the polypeptide according to any one of claims 1-11, comprising
- culturing a transformed cell according to claim 27 and any one of claims 28-32, insofar as these depend on claim 27, under conditions that facilitate that the transformed cell
30 expresses the nucleic acid fragment according to claim 12-i) and any one of claims 13-17 insofar as these depend on claim 12-i) and subsequently recovering said polypeptide, or
- preparing said polypeptide by means of solid or liquid phase peptide synthesis.

55. A method for determining whether a substance, such as an antibody, is potentially useful for treating infection with *S. aureus*, the method comprising contacting the polypeptide according to any one of claims 1-21 with the substance and subsequently establishing whether the substance has at least one of the following characteristics:

- 5 1) the ability to bind specifically to said polypeptide,
 2) the ability to compete with said polypeptide for specific binding to a ligand/receptor,
 3) the ability to specifically inactivate said polypeptide.

56. A method for determining whether a substance, such as a nucleic acid, is potentially useful for treating infection with *S. aureus*, the method comprising contacting the substance
10 with the nucleic acid fragment of any one of claims 12-17 and subsequently establishing whether the substance has either the ability to

- 1) bind specifically to the nucleic acid fragment, or
 2) bind specifically to a nucleic acid that hybridizes specifically with the nucleic acid fragment.

57. The polypeptide according to any one of claims 1-11 for use as a pharmaceutical.

15 58. The polypeptide according to any one of claims 1-11 for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with *S. aureus*.

59. The nucleic acid fragment according to any one of claims 12-17 or the vector according to any one of claims 18-24 for use as a pharmaceutical.

60. The nucleic acid fragment according to any one of claims 12-17 or the vector
20 according to any one of claims 18-24 for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with *S. aureus*.

61. The cell according to any one of claims 25-32 for use as a pharmaceutical.

62. The cell according to any one of claims 25-32 for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with *S. aureus*.

25 63. The antibody, antibody fragment or antibody analogue according to any one of claims 45-47 for use as a pharmaceutical.

64. The antibody, antibody fragment or antibody analogue according to any one of claims 45-47 for use as a pharmaceutical in the treatment, prophylaxis or amelioration of infection with *S. aureus*.




Fig. 1




Fig. 2

2/3




Fig. 3




Fig. 4


3/3

Fig. 5

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2017/054043

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K39/00 A61K39/285 C07K14/31
ADD. C12N5/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, BIOSIS, Sequence Search, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2007/118916 A1 (PUZIO PIOTR [DE] ET AL) 24 May 2007 (2007-05-24) the whole document	1-5,7-64
X	WO 2013/040142 A2 (IOGENETICS LLC [US]; BREMEL ROBERT D [US]; HOMAN JANE [US]) 21 March 2013 (2013-03-21) the whole document	1-5,7-64
X	US 2006/073161 A1 (BRETON GARY L [US]) 6 April 2006 (2006-04-06) the whole document	1-5,7-64
X	WO 2013/092985 A1 (NOVARTIS AG; CONTORNI MARIO [IT]; TARLI LORENZO [IT]; COSLOVI ANNA [IT]) 27 June 2013 (2013-06-27) the whole document	1-64
	-/-	



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

13 June 2017

Date of mailing of the international search report

21/06/2017

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Seranski, Peter

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2017/054043

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2011/127032 A1 (UNIV CHICAGO [US]; SCHNEEWIND OLAF [US]; CHENG ALICE [US]; MISSIAKAS D) 13 October 2011 (2011-10-13) the whole document -----	1-64

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2017/054043

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 5(completely); 1-4, 7-64(partially)

Polypeptide comprising an amino acid sequence with Seq-ID-N°1, fragments thereof or an assembly of amino acids derived from Seq-ID-N°1 which has essentially the same 3D conformation as in the protein from which said assembly is derived so as to constitute a B-cell epitope, said polypeptide being antigenic in a mammal; Nucleic acid sequences encoding said polypeptide and its fragments, vectors, cells and their medical use.

2. claims: 6(completely); 1-4, 7-64(partially)

Polypeptide comprising an amino acid sequence with Seq-ID-N°2, fragments thereof or an assembly of amino acids derived from Seq-ID-N°2 which has essentially the same 3D conformation as in the protein from which said assembly is derived so as to constitute a B-cell epitope, said polypeptide being antigenic in a mammal; Nucleic acid sequences encoding said polypeptide and its fragments, vectors, cells and their medical use.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2017/054043

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2007118916 A1	24-05-2007	AU 2006219823 A1 CA 2598792 A1 EP 1777296 A2 EP 1871883 A1 EP 2175034 A2 EP 2194140 A2 US 2007118916 A1 WO 2006092449 A2	08-09-2006 08-09-2006 25-04-2007 02-01-2008 14-04-2010 09-06-2010 24-05-2007 08-09-2006
WO 2013040142 A2	21-03-2013	EP 2771349 A2 WO 2013040142 A2	03-09-2014 21-03-2013
US 2006073161 A1	06-04-2006	US 7090973 B1 US 2006073161 A1	15-08-2006 06-04-2006
WO 2013092985 A1	27-06-2013	CN 104023744 A EP 2793939 A1 JP 2015500864 A US 2015044251 A1 WO 2013092985 A1	03-09-2014 29-10-2014 08-01-2015 12-02-2015 27-06-2013
WO 2011127032 A1	13-10-2011	EP 2555794 A1 JP 6042574 B2 JP 2013523818 A JP 2016175907 A US 2013136746 A1 US 2014335095 A1 US 2016175441 A1 WO 2011127032 A1	13-02-2013 14-12-2016 17-06-2013 06-10-2016 30-05-2013 13-11-2014 23-06-2016 13-10-2011